%PDF-1.3
%
5 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T0WI2P0T5T R
Ɩf
!\!Y\ !p
o
endstream
endobj
6 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T0WI2P0T5T R
Ɩf
!\!Y\ !p
o
endstream
endobj
1 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T0WI2P0T5T R
Ɩf
!\!Y\ !p
o
endstream
endobj
3 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T0WI2P0T5T R
Ɩf
!\!Y\ !p
o
endstream
endobj
4 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T0WI2P0T5T R
Ɩf
!\!Y\ !p
o
endstream
endobj
8 0 obj
<>stream
Acrobat Distiller 8.1.0 (Windows); modified using iText 4.2.0 by 1T3XT
Arbortext Advanced Print Publisher 9.0.114/W
2019-04-29T03:53:46-07:00
2019-04-16T01:55:19+05:30
application/pdf
LRB-2018-0087-ver9-Gordon_2P 173..177
uuid:9ed366d9-f19d-4068-9ac8-8158c3cc8261
uuid:3d6eb2ef-7689-44d3-b47c-420dc7baa8bb
endstream
endobj
9 0 obj
<>stream
x+ |
endstream
endobj
10 0 obj
<>stream
xS**T0T0 Bi yJ%
endstream
endobj
11 0 obj
<>stream
x+ |
endstream
endobj
12 0 obj
<>stream
xS**T0T0 Bi y8#
endstream
endobj
13 0 obj
<>stream
x+ |
endstream
endobj
14 0 obj
<>stream
xS**T0T0 Bi yS&
endstream
endobj
15 0 obj
<>stream
x+ |
endstream
endobj
16 0 obj
<>stream
xS**T0T0 Bi yA$
endstream
endobj
17 0 obj
<>stream
x+ |
endstream
endobj
18 0 obj
<>stream
xS**T0T0 Bi y\'
endstream
endobj
20 0 obj
<>stream
/GS1 gs
BT
/F5 1 Tf
9.843 0 0 9.843 72 725.1588 Tm
0 0 0 rg
0 Tc
0 Tw
[(Service)-183.9(2)-179.6(was)-189.5(the)-183.1(ACH)-178.9(group)-184(community-based)-189.5(health)-182(and)]TJ
-1.0137 -1.1174 TD
[(wellness)-461.1(services)-461.3(which)-456.9(provide)-458.2(a)-451.5(range)-462.8(of)-451.4(allied)-458.6(health,)]TJ
0 -1.1116 TD
[(nursing,)-466.1(and)-459.5(complimentary)-469.9(services)-467(to)-463.1(community-based)]TJ
T*
[(clients.)-295.9(Clients)-292.3(are)-293.6(primarily)-294.9(older)-289(than)-293.7(65)-290.2(years)-289.8(and)-292.4(have)-294.7(a)]TJ
T*
[(level)-497.7(of)-497.5(government)-492.7(funding)-497.4(to)-497.7(support)-491.4(their)-496.5(access)-500.4(and)]TJ
0 -1.1174 TD
[(provision)-280.7(of)-284.4(services.)]TJ
1.0137 -1.1116 TD
-.0164 Tc
[(Data)-502.5(co)5.5(llecti)5.4(o)-.2(n)-501.3(o)-.2(ccurr)5.6(ed)-501.3(in)-501.3(January)-501.3(an)5.5(d)-501.3(F)-.1(ebr)5.6(u)-.2(ar)5.6(y)-501.3(201)5.5(7.)]TJ
-1.0137 -1.1116 TD
-.016 Tc
[(Cl)5.8(ient)5.8(s)-374(fro)5.9(m)-375.4(bot)5.8(h)-374.2(s).4(er)6(vices)-374(w)-.7(er)6(e)-375.4(r).2(ecrui)5.8(ted)-374.2(b)5.9(ased)-368.4(on)-374.2(a)-375.4(k).2(n)5.9(o).2(wn)]TJ
0 -1.1174 TD
-.0164 Tc
[(his)5.7(t)-.3(or)5.6(y)-311.2(o)-.2(f)-311.2(c)-1.4(hr)5.6(oni)5.4(c)-312.4(e)-1.4(dema)-312.4(\(CO\))-311.2(wit)5.4(h)-311.2(or)-311.2(wi)5.4(thou)5.5(t)-311.4(a)-312.4(diagno)5.5(sis)-311(o)-.2(f)]TJ
0 -1.1116 TD
-.0157 Tc
[(lym)5(p).5(h)6.2(e)-.7(de)5.1(ma.)-301.4(R)5.2(ecr)6.3(uitm)5(en)6.2(t)-304.9(w)-.4(a)5.1(s)-304.6(o)6.2(n)-304.8(a)-300.2(vol)6.1(unt)6.1(ary)-299(b).5(as)6.4(is.)-301.4(T)-.7(h)6.2(e)-305.9(d)6.2(a)-.7(ta)]TJ
T*
-.0167 Tc
[(were)-272.4(collected)-271.2(by)-265.5(health)-265.5(pro)5.2(fess)5.4(ionals,)-267.8(i)-.6(n)5.2(c)-1.7(lu)5.2(ding)-265.5(nur)5.3(ses,)-267.8(ph)5.2(ys-)]TJ
0 -1.1174 TD
-.0161 Tc
[(iot)5.7(h).1(er)5.9(api)5.7(s).3(ts,)-278.7(e)4.7(xer)5.9(c)-1.1(is)6(e)-283.3(s)6(cientis)6(ts,)-278.7(a)4.7(nd)-276.4(per)5.9(s).3(onal)-282.3(t)5.7(rai)5.7(n).1(ers)6(.)-278.7(Th)5.8(e)-283.3(c)4.7(ur-)]TJ
0 -1.1116 TD
-.0159 Tc
[(ren)6(t)-316.6(fun)6(din)6(g)-316.5(mod)6(e)-.9(ls)-316.3(fo)6(r)-316.5(w)-.6(ou)6(nd)-316.5(an)6(d)-316.5(s).5(wel)5.9(lin)6(g)-316.5(man)6(agemen)6(t)-316.6(for)]TJ
T*
-.0163 Tc
[(the)-358.4(s).1(ervi)5.5(ces)-357(ar)5.7(e)-364.1(p)5.6(rov)5.6(ided)-357.2(p)5.6(r)-.1(imaril)5.5(y)-363(b)5.6(y)-357.2(government)5.5(-)-.1(sup)5.6(por)5.7(ted)]TJ
T*
-.0165 Tc
[(fun)5.4(din)5.4(g)-461.1(mo)5.4(del)5.3(s)-.1(,)-463.4(i)5.3(ncl)5.3(udin)5.4(g)-461.1(Home)-462.3(Care)-462.3(P)5.6(ack)5.4(ages,)-463.4(t)5.3(he)-462.3(Com-)]TJ
0 -1.1174 TD
[(mo)5.5(nwealt)5.4(h)-276.7(H)-1.1(o)5.5(m)-1.4(e)-272.1(S)-.1(up)5.5(port)-271.1(Pro)5.5(gram)-277.9(\()-.2(CHSP)5.7(\),)-273.3(or)-270.9(as)-276.5(p)5.5(a)-1.4(rt)-271.1(of)-276.7(n)5.5(or-)]TJ
0 -1.1116 TD
-.0174 Tc
[(mal)-214.5(o)-1.2(r)-208.5(rou)4.5(tine)-209.7(c)-2.4(are)-215.5(f)-1.2(o)4.5(r)-214.3(resident)-214.5(w)]TJ
12.7002 0 TD
-.0162 Tc
[(ith)5.7(in)-213.1(a)-208.5(r)0(es)5.9(iden)5.7(tial)-213.3(c)-1.2(are)-214.3(f)5.8(aci)5.6(lity)5.7(.)]TJ
-11.6864 -1.1116 TD
0 Tc
[(Calvary)-339.5(Public)-336.2(Hospital)-339.3(Bruce)-337.1(\(CPHB\))-337.6(\(Service)-340.5(3\))-336.2(is)-336.2(an)]TJ
-1.0137 -1.1174 TD
[(acute)-516(and)-517.1(subacute)-519.1(hospital)-517(facility)-518.5(serving)-515.6(the)-517.2(northern)]TJ
0 -1.1116 TD
[(suburbs)-468.1(of)-468.7(Canberra,)-471.7(Australian)-469.4(Capital)-472.2(Territory)-467.4(\(ACT\).)]TJ
T*
[(CPHB)-370(ambulatory)-377.7(services)-369.1(include)-373.2(an)-372(outpatient)-371(specialist)]TJ
0 -1.1174 TD
[(lymphedema)-293.6(service.)-291(This)-287.8(service)-293.3(runs)-286.4(out)-285.7(of)-290.1(the)-286.8(outpatient)]TJ
0 -1.1116 TD
[(physiotherapy)-454.4(department)-459.5(and)-453.7(is)-451.4(the)-453.8(hub)-452.6(in)-451.6(the)-453.9(ACT)-455.7(for)]TJ
T*
[(specialist)-481.2(management)-484.8(of)-480.2(lymphedema.)-481.3(Th)25.4(e)-468.8(C)0(P)25.7(H)0(B)-459.1(L)15(ym)19.6(-)]TJ
0 -1.1174 TD
[(ph)20.8(e)15(d)0(e)19.7(m)15(a)-186.6(S)0(e)19.8(r)0(v)26.6(i)0(c)19.5(e)-186.6(pr)26.6(ov)20.8(id)26.5(es)-176(an)-176.1(ou)26.6(tp)20.7(at)25.3(ie)19.6(nt)-175.1(se)25.6(rv)20.9(ic)25.3(e)-186.6(f)0(o)20.9(r)-185.4(pa)25.4(ti)20.6(en)25.4(ts)-174.9(fo)20.9(r)]TJ
0 -1.1116 TD
[(th)20.7(e)-365.1(w)0(h)20(o)0(l)26.5(e)-370.9(of)-359.3(th)20.7(e)-365.1(A)0(C)18.9(T)-370.9(a)15(n)0(d)-359.3(s)0(u)21(r)16.2(ro)20.9(un)26.6(di)20.7(ng)-359.3(r)16.2(e)0(g)19.7(i)0(o)26.5(n)0(s)21(.)-366.3(Th)19.6(e)-370.9(C)15.2(PH)20.1(B)]TJ
T*
[(ly)20.7(m)15(p)0(h)20.8(e)15(de)19.7(m)15(a)-301.8(t)16.1(h)0(e)19.7(r)0(a)25.5(p)0(i)20.7(s)0(t)26.7(s)-300.4(a)15(l)0(s)20.9(o)-294.8(pr)20.9(ov)26.6(id)20.7(e)-296(s)0(u)21(p)16.2(po)20.8(rt)-284.5(an)25.4(d)-294.8(c)0(o)19.7(n)0(s)21(u)16.2(lt)20.6(a)15(t)0(i)20.6(o)0(n)]TJ
T*
[(to)-273(nu)20.8(rs)26.8(in)20.7(g,)-275.2(m)15(e)0(d)19.7(i)0(c)25.3(a)0(l)19.5(,)-285.7(an)25.4(d)-289.1(a)0(l)25.3(l)0(i)20.6(e)15(d)-289.1(h)0(e)25.4(a)0(l)19.5(t)0(h)-273(p)0(r)20.9(o)16.2(fe)19.7(ss)21.2(i)16.1(o)0(n)20.8(a)0(l)25.3(s)-288.9(on)-272.9(th)20.7(e)-284.5(i)0(n)20.7(-)]TJ
0 -1.1174 TD
[(pa)19.7(t)16.1(i)0(e)19.6(n)0(t)-244.2(w)15.3(ar)19.7(ds)21(,)-251.1(b)0(u)20.8(t)-254.7(th)20.7(e)15(r)0(e)-245.2(i)0(s)-244(l)0(i)20.6(m)15(it)20.6(ed)-245.3(ca)24.3(pa)19.7(c)15(i)0(t)20.6(y)-254.5(fo)20.9(r)-254.5(c)0(o)25.4(m)0(p)19.6(r)0(e)25.5(h)0(e)19.7(n)16.2(si)20.9(ve)]TJ
0 -1.1116 TD
[(ly)20.7(m)15(p)0(h)20.8(e)15(de)19.7(m)15(a)-301.8(or)-284.4(CO)-292.1(m)15(a)0(n)19.7(a)15(ge)19.7(m)15(e)0(n)19.7(t)0(.)-286.9(T)15(hi)20.7(s)-300.4(p)16.2(re)19.7(do)26.6(mi)19.5(n)16.2(a)0(n)19.7(t)0(l)26.3(y)-300.6(ou)20.8(t)16.1(p)0(a)19.7(-)]TJ
T*
[(ti)20.6(e)15(n)0(t)-267.3(s)0(e)19.9(r)0(v)26.6(i)0(c)19.6(e)-278.7(is)-267.1(go)20.8(v)16.2(e)0(r)19.7(n)0(m)25.4(e)0(n)19.7(t)-277.7(fu)26.6(nd)20.8(e)15(d)0(.)-269.5(C)0(o)25.6(m)0(p)19.6(r)0(e)25.5(s)0(s)21.2(i)0(o)26.5(n)-283.3(g)16.2(a)0(r)19.7(m)15(en)19.7(ts)-267.1(to)]TJ
0 -1.1174 TD
[(as)19.9(s)16.4(i)0(s)20.9(t)-346.8(in)-336.4(th)26.5(e)-347.8(m)0(a)18.4(n)16.2(ag)19.7(em)24.2(en)19.7(t)-346.8(o)16.2(f)-346.6(l)0(y)20.7(m)15(ph)20.8(ed)25.4(em)18.5(a)-347.8(o)16.2(r)-346.6(C)0(O)-338.2(c)0(a)24.3(n)-346.7(be)-337.4(ob)20.8(-)]TJ
0 -1.1116 TD
[(ta)19.5(i)16.1(n)0(e)19.7(d)-306.4(t)16.1(h)0(r)20.9(o)0(u)26.6(g)0(h)-295.9(g)0(o)26.6(v)0(e)19.7(r)0(n)26.6(m)0(e)18.4(n)16.2(t-)20.7(fu)26.6(nd)20.8(ed)-291.3(bo)20.8(di)26.5(es)-296.9(to)-296.1(e)15(l)0(i)20.6(g)16.2(ib)20.7(le)-291.5(pa)19.7(ti)26.3(en)19.7(ts)]TJ
T*
[(\(u)20.9(s)16.4(u)0(a)19.7(l)0(l)26.3(y)-271.8(th)26.5(os)21(e)-267.2(r)0(e)19.7(c)15(ei)19.5(vi)26.5(ng)-255.6(an)-262.5(A)15.3(u)0(s)21(t)0(r)26.5(a)0(l)19.5(i)0(a)25.3(n)-271.8(p)16.2(e)0(n)19.7(s)0(i)26.7(o)0(n)20.8(\))0(.)]TJ
1.0137 -1.1174 TD
[(Six)-250.9(lymphedema)-253.3(physiotherapists)-256(at)-256.9(the)-252.3(CPHB)-249.1(performed)]TJ
-1.0137 -1.1116 TD
[(a)-203.8(half-day)-212.8(audit)-202.8(on)-209.5(the)-206.2(Aged)-202.3(Care)-209.3(and)-206.1(Rehabilitation)-210.8(ward)-208(on)]TJ
T*
[(October)-454.5(21,)-449.1(2016,)-457.1(and)-448(a)-451.5(full-day)-453.7(audit)-456.2(of)-451.4(other)-450.3(inpatient)]TJ
T*
[(wards)-185.9(\(including)-185.3(the)-177.4(Coronary)-189.5(Care)-180.5(Unit,)-181.8(Short)-184(Stay)-184.1(Unit,)-181.8(the)]TJ
0 -1.1174 TD
[(Medical)-208.2(Assessment)-210.6(and)-200.3(Planning)-205.9(Unit,)-204.8(surgical)-207(and)-206.1(medical)]TJ
0 -1.1116 TD
[(wards\))-394.3(on)-393.9(October)-396.9(26,)-391.5(2016.)-393.7(All)-390.3(inpatients)-399.6(present)-390.1(on)-393.9(the)]TJ
T*
[(wards)-358.7(at)-349.1(the)-355.9(time)-352.6(of)-353.5(the)-355.9(audit)-358.3(were)-353.1(approached.)-358.9(The)-351.2(study)]TJ
0 -1.1174 TD
[(was)-258.6(described)-255.2(to)-255.8(patients)-253.2(and)-257.9(consent)-251.9(was)-258.6(sought.)-251.9(If)-255.6(consent)]TJ
0 -1.1116 TD
[(was)-281.6(gained,)-283.2(a)-284.5(questionnaire-based)-285.9(interview)-289.9(and)-280.9(clinical)-283.5(as-)]TJ
T*
[(sessment)-380.5(using)-374.1(the)-373.2(LIMPRINT)-382.4(assessment)-378(tools)]TJ
7.3823 0 0 6.5614 258.8598 258.2928 Tm
(1)Tj
9.843 0 0 9.843 266.2865 253.9275 Tm
[(was)-373.8(per-)]TJ
-20.7522 -1.1174 TD
[(formed.)-450.1(Inpatients)-457(excluded)-450.2(from)-449.1(the)-453.8(study)-448.9(were)-451.1(patients)]TJ
0 -1.1116 TD
[(younger)-406.3(than)-408.9(18)-399.6(years,)-408.5(patients)-408.8(receiving)-411.1(end-of-life)-406.2(care,)]TJ
T*
[(and)-367.3(patients)-368.4(unwilling)-374.2(or)-365(unable)-366.2(to)-370.9(participate.)-372(Of)-365.9(the)-367.5(142)]TJ
0 -1.1174 TD
[(patients)-426(who)-424.6(were)-428(approached)-424.6(on)-422.7(the)-425.1(wards,)-425.4(113)-423.8(patients)]TJ
0 -1.1116 TD
[(participated)-289.1(in)-278.8(the)-281.1(study.)]TJ
1.0137 -1.1116 TD
[(The)-287.9(Western)-288.7(Health)-292.3(Chronic)-286.5(Wound)-290(Service)-287.6(\(WH)-288.6(CWS\))]TJ
-1.0137 -1.1116 TD
[(\(Service)-294.4(4\))-284.4(is)-290.1(a)-290.2(specialist)-291.1(wound)-288.6(treatment)-291.5(center)-292.4(located)-293.7(in)]TJ
0 -1.1174 TD
[(Melbourne,)-546.6(Victoria,)-551.5(within)-543.5(an)-550.5(acute)-544.8(hospital)-545.8(outpatient)]TJ
0 -1.1116 TD
[(setting.)-242.9(All)-240.6(clients)-240.6(attending)-237.3(the)-240.7(WH)-241.5(CWS)-236.8(have)-242.9(wounds)-237.7(that)]TJ
T*
[(are)-339.7(older)-335.1(than)-339.8(4)-335.2(weeks)-342.6(in)-336.4(duration.)-336.2(Chronic)-338.3(leg)-338.7(edema)-338.5(and)]TJ
0 -1.1174 TD
[(lymphedema)-449.1(on)-445.7(the)-448.1(same)-445.5(leg)-448.1(as)-446.7(the)-448.1(wound)-444.1(is)-445.6(frequently)]TJ
0 -1.1116 TD
[(found)-402.9(in)-405.5(those)-409.8(attending)-404.3(the)-407.8(clinic.)-404.4(This)-385.7(population)-387(group)]TJ
T*
[(lives)-248.6(within)-244(the)-246.5(geographical)-254.3(western)-247(suburbs)-249.2(of)-244.1(Melbourne,)]TJ
0 -1.1174 TD
[(comprising)-353.3(a)-353.6(diverse)-355.5(cultural)-351.3(mix,)-353.7(speaking)-356.7(some)-352.2(100)-348.9(lan-)]TJ
0 -1.1116 TD
[(guages)-452.2(and)-442.2(dialects.)-453.7(Attendance)-448.8(at)-452.7(the)-442.3(clinic)-452.8(involves)-447.8(no)]TJ
T*
[(charge)-303.8(to)-296.1(patients,)-297(as)-302.7(it)-296.2(is)-295.9(a)-301.8(Medicare-funded)-299.8(servic)-8.8(e.)-293.7(How-)]TJ
0 -1.1174 TD
[(ever,)-200.2(when)-196.5(the)-194.7(patients)-201.4(are)-195.7(attending)-196.9(to)-198.2(their)-197(wound)-196.5(dressings)]TJ
0 -1.1116 TD
[(outside)-348.8(the)-344.4(clinic,)-346.8(they)-345.5(mostly)-347.7(purchase)-346.1(their)-346.7(own)-349.8(dressing)]TJ
25.504 67.9184 TD
[(supplies)-269(and)-269.4(compression)-268.8(therapy,)-272.8(as)-262.4(no)-267.1(funding)-267(for)-268.2(these)-267(is)]TJ
0 -1.1174 TD
[(available)-193.5(in)-180.9(Victoria.)-188.6(All)-183(patients)-189.9(attending)-185.4(the)-188.9(clinic)-182.1(during)-185.3(a)]TJ
0 -1.1116 TD
[(10-week-per)-10.6(iod)-464.2(were)-474.1(screened)-474(to)-468.9(participate)-472.3(in)-468.9(the)-471.1(LIM-)]TJ
T*
[(PRINT)-428.9(study)-420.1(by)-422.7(the)-419.3(Clinical)-427.4(Nurse)-422(ConsultantWou)-9.7(nd/-)]TJ
T*
[(Lymp)-6.8(hedema)-310.8(who)-309.4(saw)-316.2(them)-312.2(during)-312(their)-312.2(normal)-314.4(scheduled)]TJ
0 -1.1174 TD
[(appointmen)-9.1(t.)-200.5(Fifty-ve)-206.8(of)-203.8(57)-198(patients)-207.2(attending)-208.5(the)-200.4(clinic)-210.9(had)]TJ
0 -1.1116 TD
[(chronic)-263.6(leg)-263.8(edema)-263.7(and)-257.9(agree)-9(d)-260.3(t)0(o)-255.8(participate)-264.9(in)-261.5(the)-263.8(study.)]TJ
1.0137 -1.1116 TD
[(People)-371.8(who)-361.3(attended)-369.7(Services)-369.1(1)-369.7(and)-361.6(2)-369.7(were)-364.7(not)-366.3(seeking)]TJ
-1.0137 -1.1174 TD
[(specic)-368.1(care)-370.7(for)-366.1(wounds)-364.4(or)-365(swelling)-368.1(but)-366.3(needed)-367.2(assistance)]TJ
0 -1.1116 TD
[(generally)-336.2(with)-328.1(functional)-330.5(activities)-331.7(or)-324.7(conditions.)-332.6(Those)-324.5(at-)]TJ
T*
[(tending)-222.2(Service)-218.5(3)-214.2(were)-214.9(people)-216.4(seeking)-223.1(acute)-216.5(or)-215.3(subacute)-219.6(care)]TJ
0 -1.1174 TD
[(not)-308.7(specic)-310.5(to)-307.6(wounds)-306.8(or)-301.7(swelling,)-314(whereas)-305.6(those)-311.9(attending)]TJ
0 -1.1116 TD
[(Service)-287.6(4)-277.6(had)-280.9(known)-282.8(wounds,)-281.4(which)-284.1(required)-281.9(attention.)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 313.0582 566.1353 Tm
[(Overall)-340.2(Findings)]TJ
/F5 1 Tf
9.843 0 0 9.843 323.0361 549.751 Tm
[(Across)-209.8(the)-206.2(four)-205.9(services,)-211.3(222)-204.9(participants)-207.1(were)-209.2(recruited)-209.4(to)]TJ
-1.0137 -1.1174 TD
[(participate)-403.2(in)-399.7(the)-396.3(study.)-400.5(The)-397.3(majority)-397.5(of)-399.6(participants)-402.9(were)]TJ
0 -1.1116 TD
[(female)-207.3(\(60%,)]TJ
/F6 1 Tf
5.5639 0 TD
(n)Tj
/F7 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.7142 0 TD
[(132\))-206(and)-200.3(ranged)-204.7(in)-203.9(age)-201.5(from)-201.4(22)-203.8(to)-198.2(102)-204.9(years)]TJ
-6.9462 -1.1116 TD
[(\(Tabl)-8(e)-388.2(1\).)-391.5(While)-395.1(many)-392.7(of)-388.1(the)-396.3(participants)-397.1(were)-393.5(of)-388.1(normal)]TJ
0 -1.1174 TD
[(weight)-492.7(\(41%,)]TJ
/F6 1 Tf
6.1226 0 TD
(n)Tj
/F7 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(89\),)-490.5(more)-490.6(than)-483.8(50%)-493.9(were)-491.4(obese)-485.7(\(34%,)]TJ
/F6 1 Tf
-7.5107 -1.1116 TD
(n)Tj
/F7 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(74\))-279.7(or)-284.4(morbidly)-281(obese)-278.3(\(17%,)]TJ
/F6 1 Tf
11.9456 0 TD
(n)Tj
/F7 1 Tf
.6624 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
(37\).)Tj
-13.7023 -1.1116 TD
[(Primary)-390.1(lymphedema)-391.5(was)-391(reported)-391.3(in)-388.2(7%)-389.2(of)-388.1(all)-384.9(partici-)]TJ
-1.0137 -1.1174 TD
[(pants)-697.8(\()]TJ
/F6 1 Tf
3.139 0 TD
(n)Tj
/F7 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(15\))-688.7(and)-695.6(secondary)-692.8(lymphedema/CO)-696.3(in)-693.5(43%)]TJ
-4.5271 -1.1116 TD
(\()Tj
/F6 1 Tf
.3341 0 TD
(n)Tj
/F7 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(95\))-371.9(of)-370.8(participants.)-377.5(Further)-377.4(reporting)-374.1(in)-370.9(this)-373.1(article)-374.4(re-)]TJ
-1.7222 -1.1116 TD
[(garding)-314.2(secondary)-312.7(lymphedema/CO)-310.4(will)-310.9(be)-308.6(denoted)-309.7(as)-308.4(CO,)]TJ
0 -1.1174 TD
[(which)-341.7(encompasse)-10.8(s)-335(all)-344.5(participants)-345.3(with)-339.6(edema)-344.3(for)-337.3(a)-342.1(mini-)]TJ
0 -1.1116 TD
[(mum)-357.1(of)-353.5(3)-352.4(months)-353.4(irrespective)-357.8(of)-353.5(the)-355.9(cause.)-357.8(Of)-354.4(the)-350.2(partici-)]TJ
T*
[(pants)-645.9(who)-643.5(had)-649.5(CO,)-641.1(6%)-642.6(\()]TJ
/F6 1 Tf
11.8016 0 TD
(n)Tj
/F7 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(6\))-641.5(was)-644.5(related)-650.7(to)-641.7(cancer)]TJ
-13.1897 -1.1116 TD
[(treatment,)-456.2(1%)-452.5(\()]TJ
/F6 1 Tf
6.6237 0 TD
(n)Tj
/F7 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(1\))-451.4(to)-451.6(metastatic)-455(lymphatic)-451.6(obstruction,)]TJ
-8.0118 -1.1174 TD
[(and)-286.7(93%)-286.6(\()]TJ
/F6 1 Tf
4.1873 0 TD
(n)Tj
/F7 1 Tf
.6624 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(87\))-285.5(to)-284.6(noncancer-related)-292(causes.)-289.6(Where)-286.5(swell-)]TJ
-5.5696 -1.1116 TD
[(ing)-262.6(was)-264.3(noncancer-related,)-266.6(venous)-261(problems)-264.5(were)-261(present)-263.4(in)]TJ
T*
[(80%)-200.2(\()]TJ
/F6 1 Tf
2.3672 0 TD
(n)Tj
/F7 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(70\))-199.1(of)-198(participants,)-204.8(and)-200.3(both)-200.4(immobility)-198.4(and)-200.3(obesity)]TJ
-3.7553 -1.1174 TD
[(were)-428(reported)-425.9(to)-422.8(contribute)-428.4(to)-422.8(swelling)-425.7(in)]TJ
/F11 1 Tf
18.0682 0 TD
(*)Tj
/F5 1 Tf
1.0022 0 TD
[(39%)-419.1(\()]TJ
/F6 1 Tf
2.5861 0 TD
(n)Tj
/F7 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
(34,)Tj
-23.0446 -1.1116 TD
(immobility;)Tj
/F6 1 Tf
5.034 0 TD
(n)Tj
/F7 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.7142 0 TD
[(33,)-282.1(obesity\))-286.5(of)-278.6(participants)-281.9(with)-282(CO.)]TJ
-5.4026 -1.1116 TD
[(In)-226.8(the)-223.5(facilities)-228(that)-224.7(were)-226.4(not)-222.3(dedicated)-227.9(to)-221.2(the)-223.5(management)]TJ
-1.0137 -1.1174 TD
[(of)-411.1(wounds)-410.5(\(Services)-410.5(1,)-407.7(2,)-407.7(and)-413.4(3\),)-408.8(1%)-406.4(\()]TJ
/F6 1 Tf
16.634 0 TD
(n)Tj
/F7 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.7142 0 TD
[(2\))-411.1(had)-407.6(primary)]TJ
-18.0164 -1.1116 TD
[(lymphedem)-9.1(a)-342.1(and)-350(35%)-344.2(\()]TJ
/F6 1 Tf
9.8433 0 TD
(n)Tj
/F7 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(53\))-343.1(had)-350(CO.)-347.4(The)-345.5(majority)-351.4(were)]TJ
-11.2314 -1.1116 TD
[(from)-270.5(the)-275.3(residential)-275.1(aged)-271.7(care)-272.8(facility)-270.8(where)-273.6(more)-271.7(than)-270.6(50%)]TJ
T*
(\()Tj
/F6 1 Tf
.3341 0 TD
(n)Tj
/F7 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(21\))-245.2(had)-246.4(CO,)-249.5(of)-249.8(which)-243.8(82%)-246.3(\()]TJ
/F6 1 Tf
11.3409 0 TD
(n)Tj
/F7 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(18\))-245.2(were)-249.5(venous)-249.5(related.)]TJ
-13.4374 -1.1174 TD
[(Cellulitis)-284.5(had)-280.9(occurred)-288.7(in)-278.8(the)-281.1(area)-284.3(affected)-290(by)-278.7(swelling)-281.7(in)]TJ
-1.0137 -1.1116 TD
[(37%)-499.7(\()]TJ
/F6 1 Tf
2.6667 0 TD
(n)Tj
/F7 1 Tf
.6624 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(41\))-492.8(of)-497.5(participants,)-498.5(and)-499.8(15%)-493.9(\()]TJ
/F6 1 Tf
13.1955 0 TD
(n)Tj
/F7 1 Tf
.6624 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(16\))-498.6(had)-494(been)]TJ
-18.6269 -1.1116 TD
[(hospitalize)-10.2(d)-260.3(i)0(n)-261.5(the)-263.8(past)-264.7(year)-265.9(due)-263.7(to)-261.5(cellulitis)-267.3(\(Table)-263.7(2\).)-264.8(Most)]TJ
0 -1.1174 TD
[(often,)-246.3(people)-245.2(were)-243.7(admitted)-243.1(to)-244.2(hospital)-240.6(with)-247.4(cellulitis)-244.3(on)-244.1(one)]TJ
0 -1.1116 TD
(\(69%,)Tj
/F6 1 Tf
2.7359 0 TD
(n)Tj
/F7 1 Tf
.6624 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(11\))-314.3(or)-319(two)-315.3(occasions)-318.4(\(25%,)]TJ
/F6 1 Tf
11.554 0 TD
(n)Tj
/F7 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(4\))-313.2(during)-317.7(the)-315.6(past)]TJ
-17.0602 -1.1116 TD
[(year.)-292.4(Wounds)-290.9(were)-295.6(identied)-288.9(in)-290.3(47%)-292.4(\()]TJ
/F6 1 Tf
15.7413 0 TD
(n)Tj
/F7 1 Tf
.6624 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(105\))-292.4(of)-290.1(all)-287(partic-)]TJ
-17.1236 -1.1174 TD
[(ipants)-7.8(,)-302.9(with)-310.8(leg/foot)-304.1(ulcer)-313.2(the)-304.1(most)-310.8(common)-309.7(type)-305.2(of)-307.4(wound)]TJ
0 -1.1116 TD
(\(65%,)Tj
/F6 1 Tf
2.7013 0 TD
(n)Tj
/F7 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.7142 0 TD
[(68\),)-283.2(then)-282.2(surgical)-287.6(wounds)-278(\(17%,)]TJ
/F6 1 Tf
13.4201 0 TD
(n)Tj
/F7 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.7142 0 TD
[(18\))-285.5(and)-280.9(other)]TJ
-18.8861 -1.1116 TD
[(types)-283.1(of)-284.4(wounds)-278(\(18%,)]TJ
/F6 1 Tf
9.5899 0 TD
(n)Tj
/F7 1 Tf
9.843 0 0 9.843 414.0282 199.0488 Tm
(=)Tj
/F5 1 Tf
.72 0 TD
[(19\))-279.7(\(Table)-286.7(2\).)]TJ
-9.9643 -1.1174 TD
[(The)-328.2(most)-328.1(common)-332.8(site)-328.2(of)-324.7(swelling)-333.6(were)-330.1(the)-327.1(lower)-330.2(limbs)]TJ
-1.0137 -1.1116 TD
(\(51%,)Tj
/F6 1 Tf
2.7013 0 TD
(n)Tj
/F7 1 Tf
.6624 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(112\),)-284.3(followed)-281.8(by)-278.7(the)-281.1(upper)-283.1(limbs)-277.5(\(2%,)]TJ
/F6 1 Tf
16.2654 0 TD
(n)Tj
/F7 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.7142 0 TD
[(5\))-284.4(and)]TJ
-21.7314 -1.1116 TD
[(midline)-229.4(\(2%,)]TJ
/F6 1 Tf
5.4429 0 TD
(n)Tj
/F7 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.7142 0 TD
[(4\).)-224.5(Of)-227.7(the)-223.5(110)-227.9(participants)-230.1(who)-223(had)-223.3(primary)]TJ
-6.8253 -1.1116 TD
[(lymphedem)-9.1(a)-198.1(o)0(r)-203.8(CO,)-203.4(41%)-200.2(\()]TJ
/F6 1 Tf
10.6324 0 TD
(n)Tj
/F7 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(45\))-199.1(reported)-207(their)-202.7(swelling)-206.9(was)]TJ
-12.0205 -1.1174 TD
[(well)-283.2(controlled.)]TJ
1.0137 -1.1116 TD
[(A)-324.5(number)-320(of)-324.7(comorbidities)-323.4(were)-324.4(reported,)-325.7(including)-322.5(dia-)]TJ
-1.0137 -1.1116 TD
[(betes)-324.6(mellitus)-322.6(\(20%,)]TJ
/F6 1 Tf
8.6799 0 TD
(n)Tj
/F7 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.7142 0 TD
[(44\),)-323.5(heart)-319(failure)-321.3(or)-319(ischemic)-324.6(heart)]TJ
-10.0622 -1.1174 TD
[(disease)-391.1(\(20%,)]TJ
/F6 1 Tf
6.088 0 TD
(n)Tj
/F7 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(43\),)-386.8(neurological)-391.5(disorder)-390(\(15%,)]TJ
/F6 1 Tf
13.8463 0 TD
(n)Tj
/F7 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
(34\),)Tj
-22.7105 -1.1116 TD
[(and)-286.7(peripheral)-279.7(arterial)-289.1(disease)-281.6(\(16%,)]TJ
/F6 1 Tf
15.0904 0 TD
(n)Tj
/F7 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(36\))-279.7(\(Table)-280.9(3\).)]TJ
-15.4648 -1.1116 TD
[(The)-362.8(majority)-357.1(of)-359.3(participants)-362.6(reported)-362.5(that)-357.2(they)-357(have)-363.8(had)]TJ
-1.0137 -1.1174 TD
[(swelli)-8.8(ng)-238.3(for)-245.1(more)-242.9(than)-241.8(10)-244.1(years)-243.8(\(31%,)]TJ
/F6 1 Tf
15.5858 0 TD
(n)Tj
/F7 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(34\),)-242.8(with)-241.7(less)-247.2(than)]TJ
-16.9739 -1.1116 TD
[(6)-231.5(months)-232.4(and)-229.1(25)-227.9(years)-232.2(each)-232.5(accounting)-233.6(for)-227.9(a)-232.6(further)-227.8(18%)-229(of)]TJ
T*
[(participant)-10.3(s)-277.4(\(Table)-286.7(4\).)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 62.022 749.6502 Tm
(174)Tj
46.6062 0 TD
[(GORDON)-333.7(ET)-338.7(AL.)]TJ
ET
endstream
endobj
30 0 obj
<>stream
h,=N0 F
L Ǔ, Z5_;5ijq;83bbabJ3[͆a^zx|yۿ:ڔww@~y3?kMh~Waq<Y `d@#[5R-(<eI6S 9&
Yt,z\#ATXHQMeZƧsRHXRL5xqH $p"ax3(ĞYN(=e(R8(1R4d׆' =
endstream
endobj
33 0 obj
<>stream
/GS1 gs
BT
/F3 1 Tf
8.9663 0 0 8.9663 59.7543 489.2597 Tm
0 0 0 rg
0 Tc
0 Tw
[(Service-Specic)-338.8(Information)]TJ
/F10 1 Tf
0 -1.8336 TD
[(Residential)-341.4(aged)-327.5(care)-339.3(facility)-330.2(\(Adelaide\))]TJ
/F5 1 Tf
9.843 0 0 9.843 69.7323 456.3778 Tm
[(Of)-314.1(the)-315.6(37)-307.5(participants)-322.3(at)-308.8(Service)-316.4(1,)-315.6(1)-312.1(participant)-315.6(had)-309.7(pri-)]TJ
-1.0137 -1.1116 TD
[(mary)-202.6(lymphedema)-201.4(and)-194.5(19)-198(had)-200.3(CO.)-197.6(Of)-198.9(the)-194.7(19)-198(with)-201.4(CO,)-197.6(2)-196.9(were)]TJ
0 -1.1174 TD
[(related)-385.8(to)-376.7(cancer)-385.6(and)-378.8(17)-376.6(noncancer,)-380.8(of)-382.3(which)-376.3(the)-379(majority)]TJ
0 -1.1116 TD
(\()Tj
/F6 1 Tf
.3341 0 TD
(n)Tj
/F7 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(15\))-360.4(were)-358.9(venous)-358.9(related.)-360.4(Twenty-ve)-366.7(cases)-359.9(\(68%\))-357.9(had)]TJ
-1.7222 -1.1116 TD
[(comorbidities)-311.9(with)-310.8(the)-309.9(majority)-311.1(suffering)-310.4(from)-310.8(heart)-307.4(failure)]TJ
0 -1.1174 TD
(\()Tj
/F6 1 Tf
.3341 0 TD
(n)Tj
/F7 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(8,)-396.2(22%\).)-400.5(Eleven)-401.9(\(30%\))-398.2(participants)-402.9(had)-401.9(wounds,)-402.4(73%)]TJ
-1.7222 -1.1116 TD
(\()Tj
/F6 1 Tf
.3341 0 TD
(n)Tj
/F7 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(8\))-301.7(in)-307.6(the)-304.1(leg/foot)-309.8(and)-304(17%)-309.6(\()]TJ
/F6 1 Tf
11.4157 0 TD
(n)Tj
/F7 1 Tf
.6624 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(3\))-307.4(in)-301.8(the)-309.9(hand/arm.)-303.9(Par-)]TJ
-14.5202 -1.1116 TD
[(ticipants)-300.5(mostly)-301.6(had)-292.4(swelling)-299(for)-297(less)-299(than)-299.4(6)-294.8(months)-295.8(\()]TJ
/F6 1 Tf
21.8235 0 TD
(n)Tj
/F7 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
(5\),)Tj
-23.2116 -1.1174 TD
[(12)-193.4(years)-186.2(\()]TJ
/F6 1 Tf
4.3255 0 TD
(n)Tj
/F7 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(5\),)-189.9(or)-186.5(more)-191.1(than)-190(10)-186.5(years)-191.9(\()]TJ
/F6 1 Tf
10.2868 0 TD
(n)Tj
/F7 1 Tf
.6624 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(5\).)-189.9(Of)-187.4(the)-188.9(total)-191.4(20)]TJ
-17.3828 -1.1116 TD
[(participants)-276.2(with)-270.5(swelling,)-267.9(15)-267.1(reported)-276.1(that)-265(the)-269.5(swelling)-270.2(was)]TJ
T*
[(under)-283.1(control.)]TJ
1.0137 -1.1116 TD
[(In)-267.1(this)-263.7(setting,)-265.9(the)-263.8(cost)-270.4(and)-263.7(access)-270.1(to)-261.5(services)-271.2(for)-262.4(swelling)]TJ
-1.0137 -1.1174 TD
[(and)-321.2(wounds)-318.3(is)-318.9(controlled)-324.7(and)-321.2(supplied)-321.1(for)-320(by)-313.2(the)-321.4(aged)-323.5(care)]TJ
0 -1.1116 TD
[(facility.)-429.8(Although)-424.6(edema)-424.9(was)-425.6(not)-423.9(the)-425.1(main)-427.4(reason)-423.4(for)-423.7(re-)]TJ
T*
[(maining)-212(in)-203.9(the)-206.2(care)-209.4(facility,)-210.9(it)-209.8(is)-203.7(unclear)-212.9(if)-203.9(there)-209.5(was)-206.7(adequ)-7.8(ate)]TJ
0 -1.1174 TD
[(provision)-493.8(in)-486.1(the)-488.4(funding)-491.6(models)-487(to)-491.9(support)-485.7(best)-489.3(practice)]TJ
0 -1.1116 TD
[(management)-289(of)-278.6(swelling)-281.7(and)-280.9(wounds.)]TJ
/F10 1 Tf
8.9663 0 0 8.9663 59.7543 253.5307 Tm
[(Community)-335.5(aged)-333.8(care)-332.9(services)-334.8(\(Adelaide\))]TJ
/F5 1 Tf
9.843 0 0 9.843 69.7323 237.0897 Tm
[(Of)-377.4(the)-379(17)-382.3(participants)-379.9(at)-383.6(this)-378.8(service,)-377.4(4)-381.2(participants)-379.9(had)]TJ
-1.0137 -1.1116 TD
[(CO,)-681.4(which)-675.8(were)-675.7(reported)-679.3(as)-677(noncancer-related)-683.6(venous)]TJ
T*
[(swelling.)-210.3(Only)-207(three)-209.5(participants)-212.8(had)-206.1(comorbidities,)-211.7(two)-211.6(with)]TJ
0 -1.1174 TD
[(peripheral)-360.3(arterial)-358.2(disease)-356.5(and)-350(one)-355.8(with)-351.1(a)-353.6(neurological)-356.9(dis-)]TJ
25.5097 28.8964 TD
[(order.)-332.6(One)-327.9(participant)-332.9(was)-333.4(reported)-333.7(to)-330.6(have)-329.3(a)-330.6(wound)-334.7(\(6%\),)]TJ
0 -1.1174 TD
[(which)-451.2(was)-448.6(a)-451.5(leg/foot)-448.1(ulcer.)-454.9(Of)-446.5(the)-453.8(four)-447.8(participants)-454.7(with)]TJ
0 -1.1116 TD
[(swelling,)-198.8(50%)-200.2(\()]TJ
/F6 1 Tf
6.209 0 TD
(n)Tj
/F7 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(2\))-198(had)-200.3(swelling)-201.1(present)-200(for)-199.1(510)-200.2(years)-203.4(and)]TJ
-7.597 -1.1116 TD
[(50%)-367.2(\()]TJ
/F6 1 Tf
2.5343 0 TD
(n)Tj
/F7 1 Tf
.6624 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(2\))-365(for)-371.9(more)-363.9(than)-368.6(10)-370.8(years.)-368.1(Two)-368.2(reported)-368.3(that)-368.7(the)]TJ
-3.9166 -1.1174 TD
[(swelling)-345.1(was)-350.7(under)-346.5(control)-343.2(\(50%\),)-349.8(and)-344.3(two)-344.1(reported)-345.3(that)-351.4(it)]TJ
0 -1.1116 TD
[(was)-281.6(not)-279.9(\(50%\).)]TJ
1.0137 -1.1116 TD
[(This)-489.4(setting)-498.6(is)-491.7(focused)-493.6(on)-491.8(providing)-494(community-based)]TJ
-1.0137 -1.1116 TD
[(aged)-346.6(care)-341.9(services.)-349.5(Most)-345.1(participants)-351.1(receive)-346.5(services)-346.1(for)-343.1(a)]TJ
0 -1.1174 TD
[(considerable)-294.4(amount)-291.4(of)-290.2(time,)-292.7(and)-286.7(their)-294.9(care)-290.1(is)-290.1(not)-291.4(related)-293.6(to)]TJ
0 -1.1116 TD
[(swelling)-299(or)-295.9(wounds.)-292.9(Of)-296.8(those)-300.3(with)-293.5(swelling,)-302.5(one)-292.5(participant)]TJ
T*
[(reported)-345.3(free)-346.5(treatment)-349.1(that)-345.7(was)-345(covered)-345.2(by)-342(health)-349(care)-347.7(in-)]TJ
0 -1.1174 TD
[(surance,)-411.8(whereas)-415(four)-407.5(had)-413.4(no)-411.1(insurance)-410.7(cover)-411(at)-412.4(all.)-411.3(Two)]TJ
0 -1.1116 TD
[(participants)-443.2(were)-445.3(able)-444.6(to)-440.1(pay)-442.2(for)-441(treatment,)-444.6(and)-442.2(four)-442.1(had)]TJ
T*
[(treatment)-285.7(within)-278.6(a)-284.5(reasonable)-280.5(travel)-285.6(distance.)]TJ
/F10 1 Tf
8.9663 0 0 8.9663 310.8472 319.2944 Tm
[(Hospital)-335.5(inpatient,)-336.5(Calvary)-332.2(Public)-335.3(Hospital)-335.5(\(Canberra\))]TJ
/F5 1 Tf
9.843 0 0 9.843 320.8251 302.8535 Tm
[(Of)-354.4(the)-355.9(113)-354.6(participant)-10.3(s)-352.2(a)0(t)-360.6(this)-355.8(service,)-360.1(28%)-355.7(\()]TJ
/F6 1 Tf
18.7536 0 TD
(n)Tj
/F7 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(31\))-354.6(had)]TJ
-21.1554 -1.1116 TD
[(swelling,)-285.2(of)-284.4(which)-284.1(1)-283.3(was)-287.4(primary)-286.6(lymphedema)-287.8(and)-280.9(30)-284.4(were)]TJ
T*
[(CO.)-341.6(CO)-338.2(was)-345(subdivided)-340.5(into)-338.7(two)-344.1(categories:)-345.2(2)-335.2(participants)]TJ
0 -1.1174 TD
[(had)-275.2(cancer-related)-282.9(CO)-274.8(and)-275.2(28)-272.9(noncancer-related)-286.2(CO.)-278.3(Of)-273.7(the)]TJ
0 -1.1116 TD
[(28)-272.9(participants)-276.2(with)-276.2(noncancer-related)-280.5(CO,)-278.2(14)-272.9(were)-278.3(deemed)]TJ
T*
[(to)-451.6(be)-452.6(of)-457.2(venous)-451.1(etiology.)-457.3(Overall,)-452.3(78)-457.2(comorbidities)-455.9(were)]TJ
0 -1.1174 TD
[(found;)-237.1(27%)-240.5(\()]TJ
/F6 1 Tf
5.2586 0 TD
(n)Tj
/F7 1 Tf
.6624 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(30\))-239.4(had)-240.6(heart)-238.3(failure/ischemic)-243.9(heart)-244.1(disease;)]TJ
-6.6409 -1.1116 TD
[(22%)-378.7(\()]TJ
/F6 1 Tf
2.5458 0 TD
(n)Tj
/F7 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.7142 0 TD
[(25\))-383.4(had)-378.8(neurological)-385.7(disorders;)-380.6(20%)-378.7(\()]TJ
/F6 1 Tf
15.8161 0 TD
(n)Tj
/F7 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(23\))-377.7(had)]TJ
-21.1324 -1.1116 TD
[(diabetes)-467.4(mellitus;)-473.5(and)-465.2(9%)-469.8(\()]TJ
/F6 1 Tf
11.7959 0 TD
(n)Tj
/F7 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.7142 0 TD
[(10\))-469.8(had)-465.2(peripheral)-475.5(arterial)]TJ
-13.1782 -1.1174 TD
[(disease.)-336.9(A)-336(total)-341.1(of)-336.2(38)-330.5(wounds)-341.4(were)-335.9(reported)-339.5(\()]TJ
/F6 1 Tf
18.9034 0 TD
(n)Tj
/F7 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.7142 0 TD
[(38,)-339.7(34%\),)]TJ
ET
59.754 719.49 490.167 .22668 re
f
59.754 513.638 490.167 .22675 re
f
59.754 690.803 490.167 .28345 re
f
BT
/F9 1 Tf
9.845 0 0 9.845 151.937 725.1588 Tm
(Table)Tj
/F5 1 Tf
2.9944 0 TD
(1.)Tj
/F9 1 Tf
1.2554 0 TD
[(Age,)-329.5(Gender,)-333.6(and)-337.8(Weight)-331.7(of)-337(Participants)-336.3(at)-330(Each)-334.4(Service)]TJ
/F6 1 Tf
-13.6132 -2.8562 TD
(Participants)Tj
13.6708 1.0135 TD
[(Service)-334.1(1)]TJ
-1.4108 -1.0135 TD
(\()Tj
/F5 1 Tf
.334 0 TD
(N)Tj
/F7 1 Tf
.8868 0 TD
(=)Tj
/F6 1 Tf
.7198 0 TD
[(37\))-331.2(\(100%\))]TJ
7.4228 1.0135 TD
[(Service)-339.9(2)]TJ
-1.4051 -1.0135 TD
(\()Tj
/F5 1 Tf
.334 0 TD
(N)Tj
/F7 1 Tf
.8868 0 TD
(=)Tj
/F6 1 Tf
.7198 0 TD
[(17\))-331.2(\(100%\))]TJ
7.6761 1.0135 TD
[(Service)-334.1(3)]TJ
-1.6585 -1.0135 TD
(\()Tj
/F5 1 Tf
.334 0 TD
(N)Tj
/F7 1 Tf
.8868 0 TD
(=)Tj
/F6 1 Tf
.7141 0 TD
[(113\))-338(\(100%\))]TJ
7.9295 1.0135 TD
[(Service)-334.1(4)]TJ
-1.4051 -1.0135 TD
(\()Tj
/F5 1 Tf
.334 0 TD
(N)Tj
/F7 1 Tf
.8811 0 TD
(=)Tj
/F6 1 Tf
.7198 0 TD
[(55\))-337(\(100%\))-1941.8(Total)-333.4(\()]TJ
/F5 1 Tf
9.3922 0 TD
(N)Tj
/F6 1 Tf
.7198 0 TD
(\))Tj
/F5 1 Tf
-48.6827 -1.8946 TD
(Male)Tj
/F6 1 Tf
12.7725 0 TD
(n)Tj
/F7 1 Tf
.6622 0 TD
(=)Tj
/F5 1 Tf
.7198 0 TD
[(5)-2120.1(14%)]TJ
/F6 1 Tf
6.5705 0 TD
(n)Tj
/F7 1 Tf
.668 0 TD
(=)Tj
/F5 1 Tf
.7198 0 TD
[(4)-2120.1(24%)]TJ
/F6 1 Tf
6.3862 0 TD
(n)Tj
/F7 1 Tf
.6622 0 TD
(=)Tj
/F5 1 Tf
.7198 0 TD
[(49)-2247.8(43%)]TJ
/F6 1 Tf
6.8239 0 TD
(n)Tj
/F7 1 Tf
.668 0 TD
(=)Tj
/F5 1 Tf
.7198 0 TD
[(32)-2242.1(58%)]TJ
/F6 1 Tf
6.3114 0 TD
(N)Tj
/F7 1 Tf
.835 0 TD
(=)Tj
/F5 1 Tf
.7198 0 TD
(222)Tj
-45.9589 -1.0135 TD
(Female)Tj
/F6 1 Tf
12.5191 0 TD
(n)Tj
/F7 1 Tf
.668 0 TD
(=)Tj
/F5 1 Tf
.7198 0 TD
[(32)-1867.8(86%)]TJ
/F6 1 Tf
6.5705 0 TD
(n)Tj
/F7 1 Tf
.668 0 TD
(=)Tj
/F5 1 Tf
.7198 0 TD
[(13)-1867.8(76%)]TJ
/F6 1 Tf
6.6338 0 TD
(n)Tj
/F7 1 Tf
.6622 0 TD
(=)Tj
/F5 1 Tf
.7198 0 TD
[(64)-2247.8(57%)]TJ
/F6 1 Tf
6.8239 0 TD
(n)Tj
/F7 1 Tf
.668 0 TD
(=)Tj
/F5 1 Tf
.7198 0 TD
[(23)-2242.1(42%)]TJ
-38.0928 -1.0135 TD
[(Median)-337.5(age)-333.6(\(range\))-337.5(male)-2754.5(91)-330.2(\(71102\))-3209.7(74)-330.2(\(6886\))-3709.7(74)-336(\(3690\))-3703.9(64)-336(\(2191\))]TJ
0 -1.0077 TD
[(Median)-337.5(age)-333.6(\(range\))-337.5(female)-2222.1(90)-336(\(6792\))-3456.3(76)-330.2(\(6990\))-3709.7(74)-336(\(2299\))-3703.9(70)-336(\(3089\))]TJ
0 -1.0135 TD
[(Normal)-337.5(weight)]TJ
1.002 -1.0135 TD
[(Male)-10649.1(2)-3064.5(5)0(%)-2813.1(4)-2811.2(24%)-2624.1(16)-2938.8(14%)-2935.1(8)-2937.8(15%)]TJ
/F6 1 Tf
43.4022 0 TD
(N)Tj
/F7 1 Tf
.835 0 TD
(=)Tj
/F5 1 Tf
.7198 0 TD
[(89)-330.2(\(40%\))]TJ
-44.957 -1.0135 TD
[(Female)-9253.1(19)-2564.5(51%)-2814.1(9)-2811.2(53%)-2624.1(28)-2938.8(25%)-2935.1(3)-3438.8(5)0(%)]TJ
-1.002 -1.3129 TD
[(Under)-335.2(weight)]TJ
1.002 -1.0135 TD
[(Male)-10649.1(0)-3899.5(0)-2811.2(0)-4141.4(0)-3127.9(5)-2684.5(4.4%)-2938.4(2)-3438.8(4)0(%)]TJ
/F6 1 Tf
43.4022 0 TD
(N)Tj
/F7 1 Tf
.835 0 TD
(=)Tj
/F5 1 Tf
.7198 0 TD
[(22)-330.2(\(10%\))]TJ
-44.957 -1.0135 TD
[(Female)-9754.1(4)-2563.5(11%)-2814.1(0)-4141.4(0)-3127.9(8)-2684.5(7.1%)-2938.4(3)-3438.8(5)0(%)]TJ
-1.002 -1.3129 TD
(Obese)Tj
1.002 -1.0135 TD
[(Male)-10649.1(3)-3064.5(8)0(%)-2813.1(0)-4141.4(0)-2626.9(2)0(3)-2938.8(20%)-2434.1(10)-2938.8(19%)]TJ
/F6 1 Tf
43.4022 0 TD
(N)Tj
/F7 1 Tf
.835 0 TD
(=)Tj
/F5 1 Tf
.7198 0 TD
[(74)-330.2(\(34%\))]TJ
-44.957 -1.0077 TD
[(Female)-9754.1(9)-2563.5(24%)-2814.1(4)-2811.2(24%)-2624.1(20)-2938.8(18%)-2935.1(5)-3438.8(9)0(%)]TJ
-1.002 -1.3187 TD
[(Morbidly)-337.3(obese)]TJ
1.002 -1.0135 TD
[(Male)-10649.1(0)-3899.5(0)-2811.2(0)-4141.4(0)-3127.9(8)-2684.5(7.1%)-2437.4(12)-2190.2(21.8%)]TJ
/F6 1 Tf
43.4022 0 TD
(N)Tj
/F7 1 Tf
.835 0 TD
(=)Tj
/F5 1 Tf
.7198 0 TD
[(37)-330.2(\(17%\))]TJ
-44.957 -1.0078 TD
[(Female)-9754.1(0)-3899.5(0)-2811.2(0)-4141.4(0)-3127.9(5)-2684.5(4.4%)-2437.4(12)-2190.2(21.8%)]TJ
ET
59.754 173.537 490.167 .22682 re
f
59.754 68.372 490.167 .22675 re
f
177.222 154.658 73.474 .22676 re
f
257.386 154.658 73.531 .22676 re
f
337.549 154.658 78.463 .22676 re
f
422.702 154.658 73.474 .22676 re
f
59.754 136.97 490.167 .22678 re
f
BT
/F9 1 Tf
9.845 0 0 9.845 166.3936 179.2062 Tm
(Table)Tj
/F5 1 Tf
2.9944 0 TD
(2.)Tj
/F9 1 Tf
1.2554 0 TD
[(Type)-334.4(of)-331.2(Edema,)-332.6(Cellulitis,)-338.1(and)-332(Wounds)-338.2(Per)-331(Service)]TJ
/F6 1 Tf
-3.1154 -1.8427 TD
[(Service)-334.1(1)-335(\()]TJ
/F5 1 Tf
4.4571 0 TD
(N)Tj
/F7 1 Tf
.8868 0 TD
(=)Tj
/F6 1 Tf
.7198 0 TD
[(37\))-745.8(Service)-339.9(2)-335(\()]TJ
/F5 1 Tf
6.5359 0 TD
(N)Tj
/F7 1 Tf
.8868 0 TD
(=)Tj
/F6 1 Tf
.7198 0 TD
[(17\))-751.6(Service)-334.1(3)-335(\()]TJ
/F5 1 Tf
6.5417 0 TD
(N)Tj
/F7 1 Tf
.8868 0 TD
(=)Tj
/F6 1 Tf
.7141 0 TD
[(113\))-752.6(Service)-334.1(4)-335(\()]TJ
/F5 1 Tf
7.0427 0 TD
(N)Tj
/F7 1 Tf
.8868 0 TD
(=)Tj
/F6 1 Tf
.7198 0 TD
(55\))Tj
2.0443 -1.8139 TD
(Total)Tj
/F5 1 Tf
2.4474 0 TD
(n)Tj
/F6 1 Tf
.835 0 TD
(\(%\))Tj
/F5 1 Tf
-34.9141 0 TD
(n)Tj
/F6 1 Tf
3.9043 0 TD
(%)Tj
/F5 1 Tf
4.1174 0 TD
(n)Tj
/F6 1 Tf
3.9043 0 TD
(%)Tj
/F5 1 Tf
4.4859 0 TD
(n)Tj
/F6 1 Tf
4.1577 0 TD
(%)Tj
/F5 1 Tf
4.2383 0 TD
(n)Tj
/F6 1 Tf
3.9043 0 TD
(%)Tj
/F5 1 Tf
-42.0892 -1.9003 TD
[(Primary)-337.5(lymphedema)-4876.1(1)-3577.1(3)-3197(0)-3818.9(0)-3824.7(1)-3818.9(1)-3076.1(13)-3318.9(24)-2892.8(16)-336(\(7\))]TJ
0 -1.0077 TD
[(CO/secondary)-339.7(lymphedema)-1881.7(19)-3071.3(51)-3198(4)-3317.9(2)0(4)-3324.7(3)0(0)-3324.7(2)0(7)-3071.3(4)0(2)-3318.9(7)0(6)-2892.8(9)0(4)-336(\(42\))]TJ
0 -1.0135 TD
[(Total)-335.9(%)-13908.9(5)0(4)-7015.9(3)0(4)-7649.3(2)0(8)-6895(100)]TJ
T*
[(Cancer)-338.7(related)-7710(2)-3577.1(5)-3197(0)-3818.9(0)-3824.7(3)-3818.9(3)-3577(1)-3818.9(1)-3392.8(6)-335(\(6\))]TJ
T*
[(Cellulitis)-9940.7(1)-3577.1(3)-3197(1)-3818.9(6)-3323.7(12)-3324.7(11)-3071.3(27)-3318.9(49)-2892.8(41)-336(\(18\))]TJ
0 -1.0077 TD
[(Wounds)-9797.4(11)-3071.3(30)-3198(1)-3818.9(6)-3323.7(38)-3324.7(34)-3071.3(55)-2823.7(100)-2387(105)-337(\(47\))]TJ
8.7511 0 0 8.7511 67.748 56.5795 Tm
[(CO,)-335.4(chronic)-328.4(edema.)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 59.7543 749.7069 Tm
[(LIMPRINT)-339.7(IN)-335.1(AUSTRALIA)]TJ
53.0113 0 TD
(175)Tj
ET
endstream
endobj
39 0 obj
<>stream
/GS1 gs
BT
/F5 1 Tf
9.843 0 0 9.843 62.022 595.2755 Tm
0 0 0 rg
0 Tc
0 Tw
[(with)-345.4(the)-350.2(leg)-344.4(the)-350.2(most)-345.4(common)-344.3(site)-351.2(\()]TJ
/F6 1 Tf
15.0789 0 TD
(n)Tj
/F7 1 Tf
.6624 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(20,)-345.5(59%\).)-348.7(The)-345.5(ma-)]TJ
-16.4612 -1.1116 TD
[(jority)-237.4(were)-238(classied)-237.7(as)-239.3(surgical)-241.6(wounds)-231.9(\()]TJ
/F6 1 Tf
16.7147 0 TD
(n)Tj
/F7 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(19,)-236(56%\).)-233.5(Most)]TJ
-18.1028 -1.1174 TD
[(participants)-351.1(had)-344.3(swelling)-350.9(from)-345.4(2)-340.9(t)0(o)-347.9(5)-340.9(years)-347.4(\()]TJ
/F6 1 Tf
18.4656 0 TD
(n)Tj
/F7 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(8,)-344.4(26%\))-345.3(or)]TJ
-19.8537 -1.1116 TD
[(less)-195.4(than)-195.8(6)-196.9(months)-192.1(\()]TJ
/F6 1 Tf
7.7871 0 TD
(n)Tj
/F7 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(7,)-188.8(23%\).)-198.9(Of)-193.1(the)-194.7(total)-197.1(of)-192.2(31)-198(participants)]TJ
-9.1752 -1.1116 TD
[(with)-414.5(swelling,)-417.7(29%)-413.3(\()]TJ
/F6 1 Tf
8.8354 0 TD
(n)Tj
/F7 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.7142 0 TD
[(9\))-416.9(reported)-414.4(that)-414.8(that)-414.8(it)-411.4(was)-414.1(under)]TJ
-10.2177 -1.1174 TD
(control.)Tj
1.0137 -1.1116 TD
[(Of)-302.5(the)-309.9(29)-301.7(participant)-10.3(s)-300.4(with)-310.8(swelling)-304.8(to)-307.6(their)-306.4(lower)-307.1(limbs,)]TJ
-1.0137 -1.1116 TD
[(38%)-280.8(\()]TJ
/F6 1 Tf
2.4479 0 TD
(n)Tj
/F7 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(11\))-279.7(reported)-281.9(a)-278.7(history)-284.2(of)-278.6(lower)-284.1(limb)-282.4(cellulitis.)]TJ
-2.8223 -1.1174 TD
[(In)-428.4(this)-436.4(hospital)-430.6(setting,)-433(three)-434.1(participants)-437.5(with)-431.7(swelling)]TJ
-1.0137 -1.1116 TD
[(reported)-201.3(that)-201.7(they)-195.8(did)-199.3(not)-199.3(have)-196.8(access)-206.7(to)-198.2(free)-196.7(treatment)-205.1(within)]TJ
T*
.0187 Tc
[(th)-5.4(eir)-316.4(h).3(e)-6.6(a)-.8(lt)-5.6(h)-310.7(c)-6.6(are)-317.6(s).5(y)-5.4(s).5(te)-6.6(m)-311.9(a)-6.6(nd)-316.5(two)-316.5(r)-5.4(epor)-5.4(ted)-316.5(t)-5.6(hat)-316.6(t).2(h)-5.4(e)-.8(y)-316.5(c)-.8(oul)-5.6(d)]TJ
T*
[(no)-5.3(t)-322.2(a)-.7(f)-5.3(f).5(or)-5.3(d)-322.1(t).3(o)-322.1(p)-5.3(ay)-322.1(f)-5.3(o).4(r)-322.1(c)-.7(a)-6.5(r).5(e.)-324.4(Tw)-6.2(o)-322.1(p).4(ar)-5.3(tic)-6.5(ipa)-6.5(n).4(ts)-327.7(repo)-5.3(rte)-6.5(d)-322.1(th)-5.3(at)]TJ
0 -1.1174 TD
[(tr)-5.3(eat)-5.5(ment)-500.8(w)-6.2(a)-.7(s)-500.5(n)-5.3(ot)-500.8(av)-5.3(ail)-5.5(a)-.7(ble)-507.6(w)-.4(ith)-5.3(in)-500.7(a)-501.8(r)-5.3(eas)-5.1(ona)-6.5(ble)-501.8(t)-5.5(rav)-5.3(e)-.7(l)]TJ
0 -1.1116 TD
.02 Tc
[(dista)-5.3(n)1.6(ce)-287.5(and)-286.4()1.8(ve)-287.5(we)-5.3(re)-287.5(una)-5.3(ble)-287.5(t)1.5(o)-286.4(a)-5.3(ccess)-286.2(s)1.8(ervic)-5.3(e)-281.8(due)-287.5(t)1.5(o)-286.4(t)1.5(he)]TJ
T*
.0187 Tc
[(di)-5.6(sta)-6.6(n).3(ce)-369.5(or)-368.3(l)-5.6(ack)-368.3(of)-368.3(tr)-5.4(ans)-5.2(por)]TJ
11.865 0 TD
[(t.)-364.8(A)-6.2(t)-362.6(t)-5.5(h).4(e)-369.4(C)-.6(PH)-6.2(B)-369.2(s).6(it)-5.5(e,)-364.8(s)-5.1(i).3(x)-368.2(p).4(ar)-5.3(-)]TJ
-11.865 -1.1174 TD
[(ti)-5.6(cip)-5.4(a)-.8(nts)-5.2()-500.7(s)-5.2(w)-.5(el)-5.6(lin)-5.4(g)-500.8(o).3(r)-506.5(w)-.5(o)-5.4(und)-506.5(pre)-6.6(v).3(ent)-5.6(e)-.8(d)-506.5(t).2(hei)-5.6(r)-500.7(d)-5.4(i).2(sc)-6.6(har)-5.4(g).3(e)]TJ
0 -1.1116 TD
[(fr)-5.4(om)-283.1(the)-283.1(h)-5.4(osp)-5.4(ital)-282(f)-5.4(aci)-5.6(lity)-5.4(.)]TJ
/F10 1 Tf
8.9663 0 0 8.9663 62.022 394.2424 Tm
0 Tc
[(Western)-336(Health)-332.7(Chronic)-337.1(Wound)-335.3(Service)-333.7(\()-84.3(Melbourne\))]TJ
/F5 1 Tf
9.843 0 0 9.843 72 377.8015 Tm
[(All)-568.9(participants)-569.9(at)-567.9(this)-568.9(service)-569.8(had)-563.2(swelling.)-573.2(Primary)]TJ
-1.0137 -1.1174 TD
[(lymphedema)-287.8(was)-281.6(classied)-283.8(in)-284.6(13)-278.7(cases)-285.1(\(24%\))-283(and)-280.9(CO)-286.3(in)-278.8(42)]TJ
0 -1.1116 TD
[(cases)-342.7(\(76%\),)-332.5(of)-336.2(which)-341.7(41)-336.3(were)-335.9(noncancer-related)-343.8(swelli)-8.8(ng.)]TJ
T*
[(The)-287.9(noncancer-related)-297.7(swelling)-287.5(was)-293.1(subdivided)-288.7(into)-286.9(38)-284.4(par-)]TJ
T*
[(ticipants)-231.4(\(69%\))-225.4(with)-230.2(venous-related)-233.2(swelling,)-233.3(19)-226.8(participants)]TJ
0 -1.1174 TD
[(\(35%\))-386.7(with)-385.7(immobility-related)-389.5(swelling,)-383.1(and)-384.6(in)-388.2(25)-382.3(partici-)]TJ
0 -1.1116 TD
[(pants)-237(\(45%\),)-240.3(obesity)-239.3(was)-241.3(considered)-239(to)-238.5(contribute)-238.3(to)-238.5(the)-240.7(CO.)]TJ
T*
[(The)-184.2(most)-184.1(reported)-184(comorbidities)-185.2(were)-180.4(identied)-185.3(as)-181.7(peripheral)]TJ
0 -1.1174 TD
[(arterial)-300.6(disease)-298.9(\(33%,)]TJ
/F6 1 Tf
9.0485 0 TD
(n)Tj
/F7 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(18\),)-294.7(followed)-299.1(by)-290.2(diabetes)-300.3(mellitus)]TJ
-10.4366 -1.1116 TD
(\(31%,)Tj
/F6 1 Tf
2.9029 0 TD
(n)Tj
/F7 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(17\),)-490.5(heart)-486(failure)-494(\(9%,)]TJ
/F6 1 Tf
10.0852 0 TD
(n)Tj
/F7 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(5\),)-489.4(and)-488.3(neurological)]TJ
-15.7643 -1.1116 TD
[(disorder)-309.4(\(2%,)]TJ
/F6 1 Tf
5.8115 0 TD
(n)Tj
/F7 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(1\).)-305.1(The)-305.2(duration)-309.7(of)-307.4(the)-309.9(swelling)-310.5(was)-304.6(most)]TJ
18.3043 33.2277 TD
[(commonly)-490.6(present)-493.8(for)-487(more)-484.8(than)-489.5(10)-486(years)-491.4(\(42%,)]TJ
/F6 1 Tf
21.5759 0 TD
(n)Tj
/F7 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.7142 0 TD
(23\))Tj
-22.9582 -1.1116 TD
[(\(Tabl)-8(e)-451.5(4\).)-454.9(As)-457.9(this)-453.7(was)-460.2(a)-451.5(specialist)-463.9(wound)-455.6(care)-457.1(treatment)]TJ
0 -1.1174 TD
[(servic)-8.8(e,)-236.1(100%)-241.6(of)-238.3(participants)-241.6(had)-240.6(one)-234.9(or)-238.3(more)-242.9(wounds.)-241.1(Most)]TJ
0 -1.1116 TD
[(commonly,)-344.3(the)-338.7(leg)-344.4(was)-339.2(affected)-347.6(by)-336.3(swelling)-345.1(\(95%,)]TJ
/F6 1 Tf
21.3224 0 TD
(n)Tj
/F7 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
(52\),)Tj
-22.7105 -1.1116 TD
[(and)-344.3(leg/foot)-338.6(ulcer)-342(was)-339.2(present)-344(in)-336.4(95%)-338.4(of)-336.2(all)-344.5(cases)-342.7(\()]TJ
/F6 1 Tf
21.3224 0 TD
(n)Tj
/F7 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
(52\).)Tj
-22.7105 -1.1174 TD
[(Overall,)-734.5(19)-727.9(\(35%\))-726.5(participants)-731.2(self-reported)-731.9(that)-731.6(their)]TJ
0 -1.1116 TD
[(swelli)-8.8(ng)-359.3(was)-362.2(under)-358(control,)-363.9(with)-362.6(36)-359.3(participants)-368.3(\(65%\))-357.9(re-)]TJ
T*
[(portin)-6.8(g)-271.8(that)-276.5(their)-277.6(swelling)-281.7(was)-275.9(not)-279.9(under)-277.3(control.)-277.5(Forty-nine)]TJ
0 -1.1174 TD
[(perce)-9(nt)-232.7(\()]TJ
/F6 1 Tf
3.5307 0 TD
(n)Tj
/F7 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.7142 0 TD
[(27\))-239.4(of)-232.6(participants)-241.6(reported)-241.6(a)-232.6(history)-238.1(of)-238.3(cellulitis)]TJ
-4.913 -1.1116 TD
[(in)-284.6(the)-281.1(area)-284.3(affected)-284.2(by)-278.7(swelling.)]TJ
1.0137 -1.1116 TD
.0128 Tc
[(I)-5.5(n)-449.1(the)-450.2(w)-6.4(ou)-5.6(nd)-449.1(cl)-5.7(in)-5.6(ic)-450.2(se)-6.7(tt)-5.7(in)-5.6(g,)-451.4(onl)-5.7(y)-449.1(t).1(w)-6.4(o)-449.1(par)-5.5(t).1(i)-5.7(c)-1(i)-5.7(p).2(an)-5.6(ts)-448.9(r)-5.5(e)-1(-)]TJ
-1.0137 -1.1116 TD
.0145 Tc
[(porte)-5(d)-291.9(ac)-5(ce)-5(ss)-297.4(to)-291.9(fre)-5(e)-293(trea)-5(tme)-5(n)1.9(t,)-294.2(both)-291.9(being)-291.9(w)-4.7(ork)-291.9(c)-5(ove)-5(r)-291.8(r)-3.8(e-)]TJ
0 -1.1174 TD
.0177 Tc
[(ci)5(pi)5(en)5.1(t)5(s)-.5(.)-406.2(T)3.9(he)-405(maj)5(o)5.1(ri)5(ty)-403.9(\(9)5.1(6%\))-403.8(o)-.7(f)-403.8(p)-.7(ar)5.1(ti)5(ci)5(pan)5.1(t)-.8(s)-403.7(r)-.6(epo)5.1(r)-.6(t)5(e)3.9(d)-409.6(n)5.1(o)]TJ
0 -1.1116 TD
.0151 Tc
[(a)-4.4(c)1.3(c)-4.4(e)1.3(ss)-383.2(to)-389.2(free)-384.6(tre)-4.4(a)1.3(tm)-4.5(ent.)-385.7(Three)-390.3(p)2.5(articipants)-389(r)2.5(eporte)-4.4(d)-383.4(t)2.4(hat)]TJ
T*
.013 Tc
[(t)-5.5(h).4(e)-6.5(y)-333.7(wer)-5.3(e)-334.8(un)-5.4(abl)-5.5(e)-334.8(to)-333.7(p)-5.4(a)-.8(y)-333.7(f).4(o)-5.4(r)-333.6(ca)-6.5(re.)-336(A)-.5(l)-5.5(t).3(h)-5.4(oug)-5.4(h)-333.7(o).4(n)-5.4(l).3(y)-333.7(o).4(n)-5.4(e)-334.9(pa)-6.5(r-)]TJ
0 -1.1174 TD
.0151 Tc
[(tic)-4.4(i)2.4(pant)-291.4(reported)-291.3(that)-291.4(there)-292.4(w)1.6(ere)-292.4(n)2.5(o)-291.3(s)2.7(e)-4.4(r)2.5(vic)-4.4(e)1.3(s)-291.1(a)1.3(vailable)-292.4(in)-291.3(a)]TJ
0 -1.1116 TD
.0153 Tc
[(rea)-4.2(s)2.9(onable)-332.5(travel)-325.8(dista)-4.2(n)2.7(ce)-4.2(,)-327.9()2.9(ve)-326.8(partic)-4.2(ipants)-325.4(w)-3.9(e)1.5(re)-326.8(dete)-4.2(rred)]TJ
T*
.0129 Tc
[(f)-5.4(r).3(o)-5.5(m)-277.4(acc)-6.6(es)-5.3(si)-5.6(ng)-276.2(se)-6.6(rv)-5.5(ice)-6.6(s)-276(du)-5.5(e)-271.6(t)-5.6(o)-276.2(d).3(i)-5.6(s).5(t)-5.6(a)-.9(nc)-6.6(e)-277.3(a)-.9(nd)-276.2(a)-6.6(v).3(ai)-5.6(la)-6.6(bi)-5.6(lit)-5.6(y)-276.2(o).3(f)]TJ
0 -1.1174 TD
.0177 Tc
[(pu)5.1(bl)5(ic)-278.3(t)5(r)-.6(an)5.1(sp)5.1(or)5.1(t.)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 313.0582 368.9007 Tm
0 Tc
(Conclusions)Tj
/F5 1 Tf
9.843 0 0 9.843 323.0361 352.4597 Tm
[(Across)-221.3(the)-217.7(three)-215.3(services)-225.1(that)-213.2(were)-220.7(not)-216.5(dedicated)-222.2(to)-215.4(wound)]TJ
-1.0137 -1.1116 TD
[(care,)-477.8(between)-473(28%)-470.9(and)-471(54%)-470.9(of)-468.7(participants)-472(had)-471(primary)]TJ
0 -1.1174 TD
[(lymphedem)-9.1(a)-319(o)0(r)-324.7(CO.)-330.1(The)-322.4(highest)-325.7(rate)-329.4(was)-321.9(in)-324.9(the)-327.1(residential)]TJ
0 -1.1116 TD
[(aged)-196.8(care)-197.9(facility)-195.9(where)-198.7(the)-188.9(age)-195.7(was)-195.2(higher)-197.9(than)-195.8(at)-193.6(other)-191.1(sites,)]TJ
T*
[(and)-257.9(it)-250.1(is)-249.8(likely)-255.8(that)-253.5(the)-252.3(general)-253.2(level)-255.8(of)-249.8(mobility)-258.2(was)-252.8(less.)-250.6(As)]TJ
T*
[(well)-208.3(high)-200.4(levels)-204.8(of)-203.8(comorbidities)-208.2(were)-203.4(reported)-207(and)-206.1(are)-201.4(likely)]TJ
0 -1.1174 TD
[(to)-382.5(have)-381.1(contributed)-383.4(to)-376.7(these)-382.1(presentations.)-384.1(Importantly,)-386.9(all)]TJ
0 -1.1116 TD
[(participant)-10.3(s)-352.2(presenting)-359(to)-353.7(the)-355.9(wound)-352(clinic)-354.9(\(Service)-357.8(4\))-359.3(had)]TJ
T*
[(swelli)-8.8(ng.)]TJ
1.0137 -1.1174 TD
[(This)-224.4(study)-218.6(demonstrated)-231.1(that)-218.9(within)-226.7(an)-222.2(Australian)-221.7(hospital)]TJ
-1.0137 -1.1116 TD
[(settin)-8(g,)-211.9(the)-211.9(proportion)-212.8(of)-209.5(patients)-218.7(with)-212.9(CO)-211.5(are)-212.9(predominan)-8.9(tly)]TJ
T*
[(of)-186.5(a)-180.8(noncancer-related)-188.3(cause.)-185(Currently,)-182.8(the)-183.1(referral)-185.1(pathways)]TJ
0 -1.1174 TD
[(for)-239.4(patients)-241.7(at)-239.6(risk)-240.5(of)-238.3(or)-238.3(presenting)-238(with)-241.7(CO)-234.5(related)-241.8(to)-238.5(cancer)]TJ
0 -1.1116 TD
[(treatment)-360.6(are)-356.9(well)-358(dened)-354.4(and)-355.8(understood)-357.7(by)-353.5(medical)-358.3(pro-)]TJ
T*
[(fessionals.)-408.1(This)-397.2(facilitates)-408.9(early)-399.6(detection)-399.7(and)-401.9(intervention)]TJ
0 -1.1174 TD
[(for)-187.5(this)-183(patient)-189(cohort,)-184.1(whereas)-190.4(the)-188.9(noncancer-related)-188.3(patients)]TJ
0 -1.1116 TD
[(are)-443.3(often)-438.7(referred)-438.4(at)-435.5(a)-440(much)-438.8(later)-440(stage)-439.7(or)-434.1(not)-435.4(at)-441.2(all.)-434.4(An)]TJ
T*
[(increased)-210.3(understanding)-212.5(of)-203.8(this)-206.1(cohort)-203.7(of)-209.5(patients)-207.2(will)-207.3(help)-201.5(us)]TJ
T*
[(provid)-6.7(e)-399.7(more)-404.2(timely)-401.1(and)-401.9(effective)-406.4(care)-405.3(and)-401.9(address)-401.3(better)]TJ
0 -1.1174 TD
[(referral)-288.8(pathways.)]TJ
1.0137 -1.1116 TD
[(Australia)-312.8(is)-313.2(a)-307.5(large)-313.2(country,)-311.9(and)-309.7(public)-313.3(transport)-310.6(systems)]TJ
-1.0137 -1.1116 TD
[(ar)14(e)-296(o)0(f)20.9(t)0(e)13.8(n)-294.8(di)20.7(f)15.3(cu)19.7(lt)-284.7(to)-290.3(ac)18.5(ce)18.5(ss)15.5(.)-297.2(T)0(h)19.6(e)-296(ou)15.1(tp)20.7(at)19.5(ie)19.6(nt)-290.3(ly)20.7(mp)19.6(he)19.7(de)19.7(ma)-292.6(se)19.9(r-)]TJ
0 -1.1174 TD
[(vi)14.9(ce)-350.1(at)-354.8(CP)20(HB)-355.4(\(S)21(er)19.7(vi)20.7(ce)-355.9(3\))-353.5(co)19.7(ve)19.7(rs)-353.3(al)19.5(l)-358.3(o)0(f)-353.5(t)0(h)20.7(e)-365.1(AC)18.9(T)-359.4(a)0(s)-354.5(w)0(e)18.8(l)0(l)-353.8(a)0(s)]TJ
0 -1.1116 TD
[(re)14(gi)20.7(on)20.8(al)-268.4(Ne)18.8(w)-278.4(S)0(o)21(u)0(t)14.9(h)-277.6(W)13.9(a)0(l)13.8(e)0(s)19.9(.)-274.1(Di)14.1(st)20.9(an)19.7(ce)-269.5(ha)19.7(s)-277.4(a)-278.7(si)20.9(gn)15.1(i)20.9(ca)18.5(nt)-267.3(im)19.5(pa)19.7(ct)]TJ
T*
[(on)-313.2(ac)18.5(ce)18.5(ss)21.2(in)15(g)-317.9(c)0(a)18.5(r)0(e)19.7(.)-320.2(AC)18.9(T)-319.1(H)0(e)18.8(a)0(l)19.5(t)0(h)-307.6(h)0(a)13.9(s)-317.7(id)20.7(en)19.7(ti)20.6(e)14.1(d)-317.9(a)-319(ne)19.7(ed)-308.6(to)-313.3(sh)21(if)20.7(t)]TJ
0 -1.1174 TD
[(th)15(e)-301.8(f)0(o)20.9(c)0(u)19.7(s)-300.4(of)-290.1(se)19.9(rv)20.9(ic)13.8(es)-291.2(fr)20.9(om)-291.4(th)20.7(e)-301.8(h)0(o)20.8(s)0(p)21(i)0(t)14.8(a)0(l)-291.5(t)0(o)-290.3(t)0(h)20.7(e)-301.8(co)19.7(mm)18.4(un)20.8(it)20.6(y)-300.6(e)0(n)19.7(-)]TJ
0 -1.1116 TD
[(vi)14.9(ro)20.9(nm)19.6(en)19.7(t)-485(a)0(n)19.7(d)-484.9(ha)13.9(ve)-475.7(si)20.9(nc)19.7(e)-486.1(i)0(n)20.7(t)0(r)15(o)0(d)20.8(u)0(c)19.7(e)0(d)-475.7(a)-486.1()56.5()0(h)20.9(u)0(b)-474.5(a)0(n)19.7(d)-484.9(sp)15.3(ok)20.8(e)71.5()]TJ
T*
[(mo)19.6(de)13.9(l)-341(w)0(h)20(e)0(r)14(e)-342.1(co)19.7(mp)19.6(le)19.5(x)-346.7(C)0(O)-332.4(a)0(n)13.9(d)-340.9(ly)20.7(mp)19.6(he)13.9(de)19.7(ma)-332.9(ma)18.4(na)19.7(ge)19.7(me)18.4(nt)-336.4(is)]TJ
ET
62.022 719.49 490.167 .22668 re
f
62.022 634.223 490.167 .28351 re
f
175.805 700.611 76.819 .22681 re
f
262.658 700.611 76.819 .22681 re
f
349.512 700.611 85.039 .22681 re
f
444.529 700.611 76.819 .22681 re
f
62.022 682.923 490.167 .22675 re
f
BT
/F9 1 Tf
9.845 0 0 9.845 145.7007 725.1588 Tm
(Table)Tj
/F5 1 Tf
3.0002 0 TD
(3.)Tj
/F9 1 Tf
1.2496 0 TD
[(Relevant)-332.2(Comorbidities)-337.2(for)-332.2(All)-337.8(Participants)-336.3(at)-330(Each)-334.4(Service)]TJ
/F6 1 Tf
-12.7494 -3.6624 TD
[(Relevant)-335.4(comorbidities)]TJ
11.7647 1.8197 TD
[(Service)-334.1(1)-335(\()]TJ
/F5 1 Tf
4.4571 0 TD
(N)Tj
/F7 1 Tf
.8868 0 TD
(=)Tj
/F6 1 Tf
.7141 0 TD
[(37\))-1425.3(Service)-339.9(2)-335(\()]TJ
/F5 1 Tf
7.2212 0 TD
(N)Tj
/F7 1 Tf
.8811 0 TD
(=)Tj
/F6 1 Tf
.7198 0 TD
[(17\))-1425.3(Service)-339.9(3)-329.2(\()]TJ
/F5 1 Tf
7.2155 0 TD
(N)Tj
/F7 1 Tf
1.2208 0 TD
(=)Tj
/F6 1 Tf
.7198 0 TD
[(113\))-1426.3(Service)-334.1(4)-335(\()]TJ
/F5 1 Tf
7.7165 0 TD
(N)Tj
/F7 1 Tf
.8811 0 TD
(=)Tj
/F6 1 Tf
.7198 0 TD
(55\))Tj
2.5568 -.8062 TD
(Total)Tj
/F5 1 Tf
-34.7931 -1.0135 TD
(n)Tj
/F6 1 Tf
4.244 0 TD
(%)Tj
/F5 1 Tf
4.5723 0 TD
(n)Tj
/F6 1 Tf
4.244 0 TD
(%)Tj
/F5 1 Tf
4.912 0 TD
(n)Tj
/F6 1 Tf
4.6587 0 TD
(%)Tj
/F5 1 Tf
4.7853 0 TD
(n)Tj
/F6 1 Tf
4.244 0 TD
(%)Tj
/F5 1 Tf
-44.5423 -1.8946 TD
[(Diabetes)-340.7(mellitus)-5798.1(4)-3657.7(1)0(1)-3658.7(0)-4164.4(0)-3744(2)0(3)-3825.7(2)0(0)-3618.3(1)0(7)-3411(3)0(1)-2771.8(4)0(4)]TJ
0 -1.0135 TD
[(Heart)-336.5(failure)-7697.3(8)-3657.7(2)0(2)-3658.7(0)-4164.4(0)-3744(3)0(0)-3825.7(2)0(7)-4119.3(5)-3911(9)-2770.9(4)0(3)]TJ
0 -1.0077 TD
[(Neurological)-339.2(disorder)-4028.6(7)-3657.7(1)0(9)-3658.7(1)-4164.4(6)-3744(2)0(5)-3825.7(2)0(2)-4119.3(1)-3911(2)-2770.9(3)0(4)]TJ
0 -1.0135 TD
[(Peripheral)-336.1(arterial)-340.2(disease)-2342.5(6)-3657.7(1)0(6)-3658.7(2)-3663.4(12)-3745(10)-4326.6(9)-3617.4(1)0(8)-3411(3)0(3)-2771.8(3)0(6)]TJ
ET
62.022 213.562 239.131 .28348 re
f
62.022 56.58 239.131 .22678 re
f
62.022 165.033 239.131 .22682 re
f
BT
/F9 1 Tf
9.845 0 0 9.845 78.3496 229.2094 Tm
(Table)Tj
/F5 1 Tf
3.0002 0 TD
(4.)Tj
/F9 1 Tf
1.2496 0 TD
[(Duration)-339.1(of)-331.2(Edema)-335(for)-332.2(Participants)]TJ
2.5453 -1.0077 TD
[(at)-330(Each)-334.4(Service)]TJ
/F6 1 Tf
-3.5473 -1.8427 TD
(Service)Tj
1.2266 -1.0135 TD
(1)Tj
-.6046 -1.0135 TD
(\(CO)Tj
/F5 1 Tf
-.501 -1.0077 TD
(n)Tj
/F7 1 Tf
.668 0 TD
(=)Tj
/F6 1 Tf
.7141 0 TD
(20\))Tj
2.5798 3.0347 TD
(Service)Tj
1.2266 -1.0135 TD
(2)Tj
-.6104 -1.0135 TD
(\(CO)Tj
/F5 1 Tf
-.2476 -1.0077 TD
(n)Tj
/F7 1 Tf
.668 0 TD
(=)Tj
/F6 1 Tf
.7198 0 TD
(4\))Tj
2.3265 3.0347 TD
(Service)Tj
1.2266 -1.0135 TD
(3)Tj
-.6104 -1.0135 TD
(\(CO)Tj
/F5 1 Tf
-.4952 -1.0077 TD
(n)Tj
/F7 1 Tf
.6622 0 TD
(=)Tj
/F6 1 Tf
.7198 0 TD
(31\))Tj
2.5798 3.0347 TD
(Service)Tj
1.2266 -1.0135 TD
(4)Tj
-.6104 -1.0135 TD
(\(CO)Tj
/F5 1 Tf
-.4952 -1.0077 TD
(n)Tj
/F7 1 Tf
.6622 0 TD
(=)Tj
/F6 1 Tf
.7198 0 TD
(55\))Tj
2.9657 2.0212 TD
(Total)Tj
.1958 -1.0135 TD
(\(CO)Tj
/F5 1 Tf
-.7486 -1.0077 TD
(n)Tj
/F7 1 Tf
.6622 0 TD
(=)Tj
/F6 1 Tf
.7198 0 TD
(110\))Tj
/F7 1 Tf
-22.4526 -1.9003 TD
(<)Tj
/F5 1 Tf
.5528 0 TD
(6)Tj
.4377 -1.0135 TD
(months)Tj
5.3958 1.0135 TD
7.6656 Tc
[(57)4082.8(8)4370.7(2)7665.6(0)]TJ
-6.3862 -2.0213 TD
0 Tc
(612)Tj
.9905 -1.0135 TD
(months)Tj
5.3958 1.0135 TD
7.6656 Tc
[(25)4082.8(2)3869.7(9)]TJ
-6.3862 -2.027 TD
0 Tc
[(12)-331.2(years)-2443(5)-7665.6(5)-3582.8(4)-3294.9(1)0(4)]TJ
0 -1.0135 TD
[(25)-331.2(years)-2443(2)-7665.6(8)-3582.8(9)-3294.9(1)0(9)]TJ
0 -1.0077 TD
(510)Tj
.9905 -1.0135 TD
(years)Tj
5.3958 1.0135 TD
3.3294 Tc
[(12)-506.8(2)-253.4(9)34.5(1)3329.4(4)]TJ
/F7 1 Tf
-6.3862 -2.027 TD
0 Tc
(>)Tj
/F5 1 Tf
.5528 0 TD
[(10)-278.4(years)-2443(5)-3329.4(2)-3836.2(4)-3081.8(2)0(3)-3295.9(3)0(4)]TJ
-.5528 -1.0077 TD
[(Total)-3762.2(20)-3330.4(4)-3335.2(3)0(1)-3082.8(5)0(5)-2794.9(110)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 62.022 749.6502 Tm
(176)Tj
46.6062 0 TD
[(GORDON)-333.7(ET)-338.7(AL.)]TJ
ET
endstream
endobj
43 0 obj
<>stream
/GS1 gs
BT
/F5 1 Tf
9.843 0 0 9.843 59.7543 725.1588 Tm
0 0 0 rg
0 Tc
0 Tw
[(pe)13.9(rf)20.9(or)20.9(me)18.4(d)-254.5(i)0(n)-250(t)0(h)20.7(e)-255.7(hu)15.1(b)-254.5(a)0(n)19.7(d)-254.5(no)15.1(nc)19.7(om)19.6(pl)20.7(ex)-245.3(ma)18.4(na)13.9(ge)19.7(me)18.4(nt)-244.2(oc)19.7(cu)19.7(rs)-249.6(in)]TJ
0 -1.1174 TD
[(co)13.9(m)15(m)0(u)19.6(n)0(i)14.9(t)0(y)-232.7(h)0(e)19.7(a)0(l)19.5(t)0(h)-232.7(c)0(e)18.5(n)0(t)20.7(e)0(r)14(s)0(.)-229(E)0(v)19.6(e)0(n)-233.8(t)0(h)15(e)-238.4(Me)13(lb)20.7(ou)20.8(rn)20.9(e)-244.2(m)0(e)18.4(t)0(r)20.7(o)0(p)20.8(o)0(l)14.9(i)0(t)20.6(a)0(n)19.7(-)]TJ
0 -1.1116 TD
[(ba)13.9(se)19.9(d)-277.6(w)0(o)20(u)0(n)15.1(d)-277.6(cl)19.6(in)20.7(ic)-274.2(\(S)21(er)19.7(vi)14.9(ce)-269.5(4\))-272.9(co)19.7(ve)19.7(rs)-272.7(a)-278.7(g)0(e)19.7(o)0(g)20.8(r)0(a)19.7(p)0(h)15.1(i)0(c)19.6(a)0(l)-268.4(a)0(r)19.7(e)0(a)-275.2(o)0(f)]TJ
T*
[(so)15.3(me)-258(15)20.8(69)-152(km)]TJ
7.3823 0 0 6.5614 116.3338 696.6423 Tm
(2)Tj
9.843 0 0 9.843 119.9055 692.277 Tm
(.)Tj
-5.0973 -1.1116 TD
.0071 Tc
[(T)-6.7(h).2(e)-306.2(f)-5.5(un)-5.5(di)-5.6(n)-5.5(g)-305(mo)-5.5(de)-6.7(ls)-304.8(f)-5.5(o)-5.5(r)-305(th)-5.5(e)-306.2(p)-5.5(ro)-5.5(vi)-5.6(si)-5.6(o)-5.5(n)-305(of)-305(s)-5.3(e)-6.7(rv)-5.5(ic)-6.7(es)-310.6(of)-305(t)-5.6(h).2(i)-5.6(s)]TJ
-1.0137 -1.1174 TD
.0123 Tc
[(typ)5.4(e)-289.5(vary)-288.3(bet)5.3(w)-1.2(een)-288.3(s)-.1(t)5.3(a)-1.5(t)5.3(e)-1.5(s.)-284.9(Ev)5.4(en)-288.3(wi)5.3(thi)5.3(n)-294.1(s)5.6(t)-.4(ates,)-290.6(t)-.4(h)5.4(e)-289.5(pro)5.4(vi)5.3(sio)5.4(n)]TJ
0 -1.1116 TD
.0074 Tc
[(o)-5.2(f)-494.8(s)-5(e)-6.4(rv)-5.2(ic)-6.4(es)-500.4(b)-5.2(e)-.6(t)-5.3(w)-.3(e)-6.4(e)-.6(n)-500.5(h).5(e)-6.4(a)-.6(l)-5.3(t).4(h)-500.5(r)-5.2(eg)-5.2(io)-5.2(ns)-500.4(ma)-6.4(y)-494.8(v)-5.2(ar)-5.2(y)-5.2(,)-497.1(in)-5.2(cl)-5.3(ud)-5.2(in)-5.2(g)]TJ
T*
.0119 Tc
[(dif)5.1(f)-.7(erent)-352.2(s)-.5(er)5.1(vi)4.9(ces,)-354.4(wh)5(ich)-357.8(m)3.8(ay)-357.8(b)5(e)-359(p)5(u)-.7(b)5(licly)-352.1(fu)5(nd)5(ed)-352.1(by)-352.1(go)5(v-)]TJ
0 -1.1174 TD
.0132 Tc
[(ern)6.3(m)5.1(ent)-333.6(o)6.3(r)-333.4(p).6(r)6.4(i).5(v)6.3(a)-.6(t)6.2(e)-.6(ly)-333.5(f)6.4(u).6(n)6.3(d).6(e)5.2(d).6(.)-330.1(F).7(or)-333.4(i)6.2(n).6(s)6.5(t).5(an)6.3(ce)5.2(,)-335.8(S)6.5(er)6.4(vic)5.2(e)-334.6(4)-333.5(i)6.2(s)-339(a)5.2(n)]TJ
0 -1.1116 TD
.0125 Tc
[(en)5.6(tir)5.7(el)5.5(y)-386(V)-1(i)5.5(c)-1.3(to)5.6(ri)5.5(an)-386(p)5.6(u)-.1(b)5.6(lic)-387.2(h)5.6(e)-1.3(al)]TJ
12.4928 0 TD
.0114 Tc
[(t)4.4(h)-387.1(servi)4.4(ce.)-389.4(H)3.7(ealth)-387.1(i)4.4(n)-1.2(s)4.7(urance)]TJ
-12.4928 -1.1116 TD
.0072 Tc
[(m)-6.6(a)-.8(k)-5.4(e)-.8(s)-327.8(n).3(o)-328(d).3(i)-5.5(f).4(f)-5.4(e)-6.6(re)-6.6(nc)-6.6(e)-323.4(a)-6.6(nd)-328(do)-5.4(es)-327.8(no)-5.4(t)-322.3(c)-6.6(ov)-5.4(er)-327.9(co)-5.4(st)-5.5(s)-322(f)-5.4(o)-5.4(r)-322.2(dr)-5.4(e)-6.6(s).5(s)-5.2(i)-5.5(ng)]TJ
0 -1.1174 TD
.0115 Tc
[(sup)4.6(p)-1.1(l)4.5(i)-1.2(es)-438.7(or)-433.1(co)4.6(mp)4.6(res)4.8(s)-.9(i)4.5(o)-1.1(n)-438.9(t)4.5(herapy.)-435.4(S)4.8(e)-2.3(r)4.7(v)-1.1(ice)-440(3)-433.1(\(CPHB\))-438.8(i)4.5(s)-438.7(a)]TJ
0 -1.1116 TD
[(pub)4.5(li)4.4(c)-232.8(h)-1.2(eal)4.4(t)-1.3(h)-231.6(s)-1(erv)4.5(i)-1.3(ce;)-231.7(t)-1.3(h)4.5(e)-2.4(r)4.6(e)-2.4(fo)4.5(re,)-233.9(p)-1.2(ati)4.4(e)-2.4(n)4.5(t)-1.3(s)-231.4(d)-1.2(o)-231.6(n)4.5(ot)-231.7(pay)-231.6(f)-1.2(o)4.5(r)-237.3(car)4.6(e)]TJ
T*
.012 Tc
[(but)-536.4(h)5.1(a)-1.8(v)5.1(e)-543.2(t)5(o)-536.3(pu)5.1(rch)5.1(a)-1.8(s)5.3(e)-537.4(their)-536.2(o)-.6(wn)-536.3(co)5.1(mp)5.1(ressi)5(on)-536.3(garmen)5.1(ts)5.3(.)]TJ
T*
[(Co)5(mp)5(res)5.2(s)-.5(i)4.9(o)-.7(n)-473(g)-.7(arment)4.9(s)-478.6(m)3.8(ay)-478.8(b)5(e)-479.9(p)5(a)-1.9(r)5.1(tiall)4.9(y)-478.8(o)5(r)-478.7(f)5.1(ul)4.9(ly)-473(fu)5(nded)]TJ
0 -1.1174 TD
[(thr)5.3(o)-.5(u)5.2(g)-.5(h)-357.6(g)-.5(o)5.2(v)-.5(ernment-)5.3(fu)5.2(nded)-357.6(s)-.3(ch)5.2(emes)-357.4(fo)5.2(r)-363.3(e)4.1(li)5.1(gi)5.1(ble)-358.8(p)5.2(ati)5.1(e)-1.7(n)5.2(t)-.6(s)5.4(.)]TJ
0 -1.1116 TD
[(Occasio)5.2(n)-.5(all)5.1(y)-.5(,)-233.2(p)5.2(at)5.1(ient)5.1(s)-230.7(a)-1.7(re)-226.3(be)-232.1(abl)5.1(e)-232.1(to)-230.9(u)5.2(s)-.3(e)-232.1(t)5.1(hei)5.1(r)-230.9(pr)5.3(iv)5.2(at)5.1(e)-232.1(h)-.5(ealt)5.1(h)]TJ
T*
.0124 Tc
[(ins)5.7(u)-.2(r)5.6(a)-1.4(n)5.5(c)-1.4(e)-462.2(t)-.3(o)-466.7(h)5.5(el)5.4(p)-466.7(p)5.5(ay)-461(for)-461(co)5.5(mp)5.5(ressi)5.4(on)-461(garment)5.4(s)0(.)-463.3(M)4.6(ean-)]TJ
0 -1.1174 TD
.0119 Tc
[(wh)5(ile,)-475.3(c)3.9(os)5.2(ts)-472.8(related)-473(t)-.8(o)-473(t)4.9(he)-474.2(man)5(a)-1.9(g)5(e)-1.9(men)5(t)-473.1(of)-473(swel)4.9(li)4.9(ng)-473(an)5(d)]TJ
0 -1.1116 TD
.0115 Tc
[(wo)4.6(und)4.6(s)-335(i)4.5(n)-335.2(a)3.5(ged)-335.2(c)-2.3(are)-330.6(s)-.9(erv)4.6(i)-1.2(ces)-335(a)3.5(re)-330.6(paid)-329.4(fro)4.6(m)-336.4(a)-330.6(bu)4.6(nd)4.6(led)-335.2(f)-1.1(ee)]TJ
T*
[(that)-277.7(has)-283.1(n)4.6(o)-277.6(s)-.9(peci)4.5(c)-278.7(allo)4.6(cati)4.5(on)4.6(.)]TJ
1.0137 -1.1174 TD
.0131 Tc
[(Th)6.2(e)-490.3(h)6.2(igh)-483.3(r).5(at)6.1(es)-488.9(o)6.2(f)-489.1(ce)5.1(ll)6.1(ul)6.1(it)6.1(is)-488.9(a)5.1(t)-489.2(Se)5.1(rvi)6.1(ce)-484.5(4)-489.1(\().5(a)-490.3(d)6.2(ed)6.2(ic)5.1(ate)5.1(d)]TJ
-1.0137 -1.1116 TD
.0122 Tc
[(wo)5.3(und)-340.2(clin)5.3(ic\))-346(m)4.1(ig)5.3(ht)-340.4(reect)-340.4(th)5.3(at)]TJ
13.6505 0 TD
.007 Tc
[(c)-6.8(e)-1(l)-5.7(l)0(u)-5.6(l)-5.7(it)-5.7(is)-351(is)-351(bo)-5.6(t)-5.7(h)-345.4(a)-346.6(r)-5.6(is)-5.4(k)-345.4(o)-5.6(f)]TJ
-13.6505 -1.1116 TD
.0124 Tc
[(an)5.5(d)-351.6(a)-352.7(r)5.6(i)-.3(s)5.7(k)-351.6(fo)5.5(r)-351.5(C)4.5(O.)-348.1(Cert)5.4(ai)5.4(nly)5.5(,)-348.1(th)5.5(ere)-347(w)-1.1(o)5.5(u)-.2(l)5.4(d)-351.6(be)-347(benet)-345.9(fro)5.5(m)]TJ
0 -1.1174 TD
.0091 Tc
[(lymphe)-4.7(de)-4.7(ma)-4.7(-related)-383.7(a)-4.7(s)-3.3(se)-4.7(ss)]TJ
11.3236 0 TD
.0132 Tc
[(m)5.1(e)-.6(nt)-379.7(a)5.2(n).6(d)-379.6(m)5.1(a)5.2(n).6(ag)6.3(em)5.1(en)6.3(t)-379.7(f).6(o)6.3(r)-379.5(th)6.3(is)]TJ
-11.3236 -1.1116 TD
.0126 Tc
[(gro)5.7(up)5.7(.)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 310.8472 725.7825 Tm
0 Tc
(Acknowledgments)Tj
/F5 1 Tf
9.843 0 0 9.843 320.8251 709.3416 Tm
[(In)-376.5(kind)-384.7(support)-382(from)-379.9(Aged)-386.6(Care)-382.1(Housing)-382.9(Group)-380.7(\(South)]TJ
-1.0137 -1.1116 TD
[(Australia\),)-536.1(Calvary)-535.3(Public)-532(Hospital)-529.4(\(ACT\))-8.5(,)-527.6(and)-534.4(Western)]TJ
0 -1.1174 TD
[(Health)-280.8(Chronic)-286.5(Wound)-278.5(Service)-281.8(\(Victoria\).)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 310.8472 665.5179 Tm
[(Author)-332.4(Disclosure)-336.7(Statement)]TJ
/F5 1 Tf
9.843 0 0 9.843 320.8251 649.077 Tm
[(No)-279.5(competing)-284.4(nancial)-283.1(interests)-282.9(exist.)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 310.8472 627.1368 Tm
(Reference)Tj
/F5 1 Tf
9.2951 0 0 9.2951 310.8472 611.0928 Tm
[(1.)-500.4(Moffatt)-453.2(CJ,)-455.6(Susie)-457.7(M,)-456.9(Mercier)-456.1(G,)-459.2(Quere)-458.3(I,)-453.9(Franks)-454.7(P.)-454.5(The)]TJ
1.2503 -1.1284 TD
[(development)-250.5(and)-248.6(validation)-251.5(of)-252.7(the)-248(LIMPRINT)-256(methodology.)]TJ
0 -1.1223 TD
[(Lymphat)-335.5(Res)-331.8(Biol.)-333.6(\(Suppl\))]TJ
9.843 0 0 9.843 438.803 548.7872 Tm
[(Address)-331.9(correspondence)-343.5(to:)]TJ
/F6 1 Tf
-5.2817 -1.1116 TD
[(Sue)-332.8(J.)-334(Gordon,)-333.3(PhD,)-337.1(BaAppSc)-333.8(\(Physio\),)]TJ
8.1039 -1.1116 TD
[(GCEd,)-333.5(GDMngtPhD)]TJ
-6.5142 -1.1174 TD
[(Chair)-334.8(of)-336.4(Restorative)-339.3(Care)-334.7(in)-330.6(Ageing)]TJ
-1.4975 -1.1116 TD
[(College)-333.9(of)-336.4(Nursing)-336.8(and)-331.6(Health)-337.2(Sciences)]TJ
8.5704 -1.1116 TD
[(Flinders)-339.3(University)]TJ
4.3371 -1.1116 TD
(Adelaide)Tj
-.1555 -1.1174 TD
(Australia)Tj
-10.8974 -2.1253 TD
(E-mail:)Tj
/F5 1 Tf
3.3925 0 TD
[(sue.gordon@inder)-10.3(s.edu.au)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 59.7543 749.7069 Tm
[(LIMPRINT)-339.7(IN)-335.1(AUSTRALIA)]TJ
53.0113 0 TD
(177)Tj
ET
endstream
endobj
46 0 obj
<>stream
8;X]O>EqN@%''O_@%e@?J;%+8(9e>X=MR6S?i^YgA3=].HDXF.R$lIL@"pJ+EP(%0
b]6ajmNZn*!='OQZeQ^Y*,=]?C.B+\Ulg9dhD*"iC[;*=3`oP1[!S^)?1)IZ4dup`
E1r!/,*0[*9.aFIR2&b-C#soRZ7Dl%MLY\.?d>Mn
6%Q2oYfNRF$$+ON<+]RUJmC0InDZ4OTs0S!saG>GGKUlQ*Q?45:CI&4J'_2j$XKrcYp0n+Xl_nU*O(
l[$6Nn+Z_Nq0]s7hs]`XX1nZ8&94a\~>
endstream
endobj
48 0 obj
<>stream
8;Z\7#nFg+%.!pXR-u06:tI=dZ_U9h(5Id)@jbt=6lQ.`#!#q&]'^.V,LPMj_f-=_
rM8m,=QEDEm"VLXGT`KgS4=Srg8:s9cS"1Z>%h(i:!ts-c,D7&+S9Lta.LhfnQ[=r
bN%!eT[MVO;)Q=@Hse#]CoE`!S>-qa&N=`M>MLY!W%6l*\*4L39'%,!dQ'GTO-1C
1.-DuJLnp`W:BY"d&eK5Z1F@N;%\OR0Y"2\I^WRH*1)IQp@t7d+^nFbR%eYQqn9Qb
3V%3aUmYJUE9ZWh'tH%/MlVo=FZF^KrlsmU]ES@HP$Uc~>
endstream
endobj
21 0 obj
<>stream
8;Z\7d14&:#jhTk+MY7Y=ZZcsKSXeCH!/\j]K6iWd2SK5Nm'TBQqsV,%P-URhm8''
a$L8O=Qgb<%mCc!fH.#u/'Z8bR$_WT896U=,,3K$ntmnFbMDp92;0arrCUd_@VlL.
E:/L:,Sce4OBWML0@J,W-eJ2rVK!q`SR7nErc*i/KgWC
endstream
endobj
34 0 obj
<>stream
8;Z\7CO3l@%.jENaE?'(8?e4n$mt;S8VWOH4*X7rTl`gXT[ID.
mU"qjO(?ffk92_p+%gq]A9VmR0&@:I6a'-g"&n5P"j6i3O&au1P.d9M`hf[2^oX+]
HaP]R`\l!%($_trSEiQQ>G/arU(k\lkL*<]?oj6NiMk,p.-?t'G=Gcd@"G`o0s+UQ
i9>5.I@n&/%&?Nn3Q>(WgloTs*7K%;#,Xo>iYpE]p4Oe3m)^hlcMQ2&Xshn^]Y*i6
?g-b]'4,"5Lti4tS7u-/8*,*O]VC/S'_Q,Dh?@3gMn0kLMkPgml^XSpMo$GPQQ<6K
18?A^6![NO!A;'imnJT9:.=emKM+O:2YYh\5T_q@d%!60
endstream
endobj
40 0 obj
<>stream
8;Z\7>7SOn%-.='b]P7,?%KWt@G=;IM7!L,gU&CUH=A1(>FBP$4e9LUT<$:(q):@=D;)KW&\nkfp]$Xbgu!!&u0fW
P*_5`JO-Vkj6QuTkcFnO%=g[*46Mt(qm9E]hYunMeQ\\CdW50+$L92:4@4n*r.6b?
])d,2TR7=@_Ce%.5S7&rqRVPYM0RV`.h%N*mBOID[WWK@'5Q@M..75>Hf!*pEZ+dc
PMg!a1Rc2Mr$-hpY8:.!J2FG(@>eOnPPJlE5S@hV7oM
*%ONqoY*nub(+`!]TU=`"r#Uu<[TNlmf-O5F?7]&3[1(M7H>+X>k&^4G,9=k~>
endstream
endobj
44 0 obj
<>stream
8;Z\u;%A+!$q%T*"a:t#2,S<3'F+-UpS5`2g6/*7koa9e=7k6-St\e?YP1-SWXW>R
]6nnm[1rl6&9BoV@t5?+-="
=#0oG9@N=G$RpBBnl>(XhcEfn
endstream
endobj
52 0 obj
<>
endobj
53 0 obj
<>stream
H|U]o0}Wirro;{ue
ú=B4Bk;T .Vs9:9Kx18` Kf &?3hh-@K>hxYcX[riӗE: E+ը۶+Z\!pdpT_j
ThRc<-w[RJiݬ!cH]D$Fm|-92vy:2n7'>4fHtr
X
KlVCm87"D4
!3VfZY`MXx8СP}Eq3lqZ4άky
R1Fa
RY0fo(,n8 GBmj͗#
+YF6liV" ϛ?Ų7bg1=IYT[wQOD
hAP%s(DYg,jU$d۶ѣo?>k"[F`1uGaFs( P Bg}z!%l3ӗ*A/^Vh_6;/ݸ{uSw^$[w-_? ~jq
endstream
endobj
54 0 obj
<>stream
H\UM6ϯK$`@nFn2[&/"mf4$70;ʭUÜ?}x(|
JUݟ~q0QUċ$2dIe%Il4Dkb\a1aJJ%hu
n\D-l
B0s҈k4>ɴˈtJEQ%鶘6V
3u$hiĿ$ {u'31xO_~??%1\;oP 䨀p͠-"yȢbZo߭#Y(H$Qy' w4PU4! 0F